OA21204A - Compounds as modulators of bisphosphoglycerate mutase for the treatment of sickle cell disease. - Google Patents
Compounds as modulators of bisphosphoglycerate mutase for the treatment of sickle cell disease. Download PDFInfo
- Publication number
- OA21204A OA21204A OA1202300101 OA21204A OA 21204 A OA21204 A OA 21204A OA 1202300101 OA1202300101 OA 1202300101 OA 21204 A OA21204 A OA 21204A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- compound
- heterocyclyl
- pharmaceutically acceptable
- acceptable sait
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 312
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 title claims abstract description 38
- 102100036200 Bisphosphoglycerate mutase Human genes 0.000 title claims abstract description 38
- 208000007056 sickle cell anemia Diseases 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 149
- 125000000623 heterocyclic group Chemical group 0.000 claims description 145
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 125000005842 heteroatom Chemical group 0.000 claims description 72
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 60
- 125000001188 haloalkyl group Chemical group 0.000 claims description 60
- -1 pyrazolylene Chemical group 0.000 claims description 57
- 125000005843 halogen group Chemical group 0.000 claims description 56
- 125000004043 oxo group Chemical group O=* 0.000 claims description 52
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 41
- 229910052717 sulfur Inorganic materials 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 33
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000002947 alkylene group Chemical group 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000005549 heteroarylene group Chemical group 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000002619 bicyclic group Chemical group 0.000 claims description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 14
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 12
- 125000005557 thiazolylene group Chemical group 0.000 claims description 12
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000005551 pyridylene group Chemical group 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical compound [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 3
- 125000005576 pyrimidinylene group Chemical group 0.000 claims description 3
- 125000005556 thienylene group Chemical group 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 152
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 199
- 235000019439 ethyl acetate Nutrition 0.000 description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- 229910001868 water Inorganic materials 0.000 description 62
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 54
- 230000015572 biosynthetic process Effects 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 51
- 229940093499 ethyl acetate Drugs 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000007787 solid Substances 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 41
- 230000002829 reductive effect Effects 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 32
- 239000012267 brine Substances 0.000 description 31
- 239000003208 petroleum Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000003480 eluent Substances 0.000 description 27
- 238000010898 silica gel chromatography Methods 0.000 description 27
- 239000000377 silicon dioxide Substances 0.000 description 27
- 239000000463 material Substances 0.000 description 24
- 125000004093 cyano group Chemical group *C#N 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 238000004809 thin layer chromatography Methods 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 201000010099 disease Diseases 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 14
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 14
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 239000004698 Polyethylene Substances 0.000 description 13
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 13
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000011550 stock solution Substances 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 10
- 150000003852 triazoles Chemical class 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 9
- IXJPXMZRCJBJBB-UHFFFAOYSA-N 4-(4-bromo-1,3-thiazol-2-yl)-2,3,6-trifluorophenol Chemical compound OC(C(F)=CC(C1=NC(Br)=CS1)=C1F)=C1F IXJPXMZRCJBJBB-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- UKAJDOBPPOAZSS-UHFFFAOYSA-N ethyl(trimethyl)silane Chemical compound CC[Si](C)(C)C UKAJDOBPPOAZSS-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 8
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- JTFHAQOEYDUKNY-UHFFFAOYSA-N (5-bromo-4-methyl-1,3-thiazol-2-yl)methanamine Chemical compound CC=1N=C(CN)SC=1Br JTFHAQOEYDUKNY-UHFFFAOYSA-N 0.000 description 6
- QIXXLCJOJGHZJB-UHFFFAOYSA-N (5-bromo-4-methyl-1,3-thiazol-2-yl)methanol Chemical compound CC=1N=C(CO)SC=1Br QIXXLCJOJGHZJB-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000012964 benzotriazole Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000011535 reaction buffer Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- HBWDCKASDYTHCZ-UHFFFAOYSA-N [5-(6-chloropyridin-2-yl)-4-methyl-1,3-thiazol-2-yl]methanol Chemical compound CC1=C(C2=NC(Cl)=CC=C2)SC(CO)=N1 HBWDCKASDYTHCZ-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- HTJWUNNIRKDDIV-UHFFFAOYSA-N bis(1-adamantyl)-butylphosphane Chemical compound C1C(C2)CC(C3)CC2CC13P(CCCC)C1(C2)CC(C3)CC2CC3C1 HTJWUNNIRKDDIV-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052681 coesite Inorganic materials 0.000 description 5
- 229910052906 cristobalite Inorganic materials 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 229910052682 stishovite Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 229910052905 tridymite Inorganic materials 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- ZLTMIEKRKOYNPZ-UHFFFAOYSA-N methyl N-[(5-bromo-4-methyl-1,3-thiazol-2-yl)methyl]carbamate Chemical compound CC(N=C(CNC(OC)=O)S1)=C1Br ZLTMIEKRKOYNPZ-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- LYBOTVJZCONKDN-UHFFFAOYSA-N (2-amino-2-sulfanylideneethyl) benzoate Chemical compound NC(=S)COC(=O)C1=CC=CC=C1 LYBOTVJZCONKDN-UHFFFAOYSA-N 0.000 description 3
- CQMPPPAHJBQCOY-UHFFFAOYSA-N (4-methyl-1,3-thiazol-2-yl)methanol Chemical compound CC1=CSC(CO)=N1 CQMPPPAHJBQCOY-UHFFFAOYSA-N 0.000 description 3
- JESMSCGUTIEROV-RTWAVKEYSA-N (5as,6r,9s,9as)-1-oxo-6-propan-2-ylspiro[3,5a,6,7,8,9a-hexahydro-2-benzoxepine-9,2'-oxirane]-4-carboxylic acid Chemical compound C([C@@H]([C@@H]1[C@@H]2C(OCC(=C1)C(O)=O)=O)C(C)C)C[C@]12CO1 JESMSCGUTIEROV-RTWAVKEYSA-N 0.000 description 3
- MKEJZKKVVUZXIS-UHFFFAOYSA-N 2,4-dibromo-1,3-thiazole Chemical compound BrC1=CSC(Br)=N1 MKEJZKKVVUZXIS-UHFFFAOYSA-N 0.000 description 3
- UJRZUFNUBSHLDQ-UHFFFAOYSA-N 3-bromo-2,5-difluoro-6-nitroaniline Chemical compound BrC=1C(=C(N)C(=C(C=1)F)[N+](=O)[O-])F UJRZUFNUBSHLDQ-UHFFFAOYSA-N 0.000 description 3
- ZFHGAOPLTHSAQQ-UHFFFAOYSA-N 4-bromo-2,3,6-trifluorophenol Chemical compound OC1=C(F)C=C(Br)C(F)=C1F ZFHGAOPLTHSAQQ-UHFFFAOYSA-N 0.000 description 3
- FWBWMUKWNHRVEE-UHFFFAOYSA-N 5-bromo-3-fluoro-2-hydroxybenzonitrile Chemical compound OC1=C(F)C=C(Br)C=C1C#N FWBWMUKWNHRVEE-UHFFFAOYSA-N 0.000 description 3
- XHUUDESMAXMTMQ-UHFFFAOYSA-N 5-bromo-4-methyl-2-(pyridazin-3-yloxymethyl)-1,3-thiazole Chemical compound CC(N=C(COC1=CC=CN=N1)S1)=C1Br XHUUDESMAXMTMQ-UHFFFAOYSA-N 0.000 description 3
- VKMHSOBMDJQJIP-UHFFFAOYSA-N 5-bromo-4-methyl-2-(pyridin-2-yloxymethyl)-1,3-thiazole Chemical compound CC(N=C(COC1=NC=CC=C1)S1)=C1Br VKMHSOBMDJQJIP-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 229930010555 Inosine Natural products 0.000 description 3
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920002732 Polyanhydride Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- AMCQNAFTZBNILI-UHFFFAOYSA-N cyanomethyl benzoate Chemical compound N#CCOC(=O)C1=CC=CC=C1 AMCQNAFTZBNILI-UHFFFAOYSA-N 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229960003786 inosine Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- YKRLKKRBXIELOW-UHFFFAOYSA-N (4-methyl-1,3-thiazol-2-yl)methyl benzoate Chemical compound CC1=CSC(COC(=O)C=2C=CC=CC=2)=N1 YKRLKKRBXIELOW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FEWBODJQASUDNH-UHFFFAOYSA-N 2,3,6-trifluoro-4-[4-[4-methyl-2-(pyrimidin-2-yloxymethyl)-1,3-thiazol-5-yl]-1,3-thiazol-2-yl]phenol Chemical compound CC1=C(C2=CSC(C(C=C(C(O)=C3F)F)=C3F)=N2)SC(COC2=NC=CC=N2)=N1 FEWBODJQASUDNH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JMAIPZLTIUUWRZ-UHFFFAOYSA-N 2-[[5-(4-bromo-1,3-thiazol-2-yl)-4,7-difluorobenzotriazol-2-yl]methoxy]ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCN(N=C1C(F)=C2)N=C1C(F)=C2C1=NC(Br)=CS1 JMAIPZLTIUUWRZ-UHFFFAOYSA-N 0.000 description 2
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 2
- IQPPBXPNFCHLER-UHFFFAOYSA-N 3-fluoro-2-hydroxybenzonitrile Chemical compound OC1=C(F)C=CC=C1C#N IQPPBXPNFCHLER-UHFFFAOYSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- KAYQXTWAXUZNFE-UHFFFAOYSA-N 4-bromo-2-(4,7-difluoro-2H-benzotriazol-5-yl)-1,3-thiazole Chemical compound FC(C1=C2N=NN1)=CC(C1=NC(Br)=CS1)=C2F KAYQXTWAXUZNFE-UHFFFAOYSA-N 0.000 description 2
- HOMTUNZZMXEENT-UHFFFAOYSA-N 5-(6-chloropyridin-2-yl)-4-methyl-2-(pyrimidin-2-yloxymethyl)-1,3-thiazole Chemical compound CC1=C(C2=NC(Cl)=CC=C2)SC(COC2=NC=CC=N2)=N1 HOMTUNZZMXEENT-UHFFFAOYSA-N 0.000 description 2
- PSLAFSHHGGUKTA-UHFFFAOYSA-N 5-(6-chloropyridin-2-yl)-4-methyl-2-[(5-methylpyrimidin-2-yl)oxymethyl]-1,3-thiazole Chemical compound CC1=C(C2=NC(Cl)=CC=C2)SC(COC2=NC=C(C)C=N2)=N1 PSLAFSHHGGUKTA-UHFFFAOYSA-N 0.000 description 2
- CXPVEXBQNMUJOC-UHFFFAOYSA-N 5-bromo-4-methyl-2-(pyrimidin-2-yloxymethyl)-1,3-thiazole Chemical compound CC(N=C(COC1=NC=CC=N1)S1)=C1Br CXPVEXBQNMUJOC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FALVOUBUUVZXGE-UHFFFAOYSA-N CC1=C(C2=CSC(C(C=C(C3=C4N=NN3COCC[Si](C)(C)C)F)=C4F)=N2)SC(CNC(OC)=O)=N1 Chemical compound CC1=C(C2=CSC(C(C=C(C3=C4N=NN3COCC[Si](C)(C)C)F)=C4F)=N2)SC(CNC(OC)=O)=N1 FALVOUBUUVZXGE-UHFFFAOYSA-N 0.000 description 2
- FPKYEDFYYQJBIG-UHFFFAOYSA-N C[Si](C)(C)CCOCN1N=NC2=C1C(F)=CC(C1=NC(Br)=CS1)=C2 Chemical compound C[Si](C)(C)CCOCN1N=NC2=C1C(F)=CC(C1=NC(Br)=CS1)=C2 FPKYEDFYYQJBIG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- OEFZXDSNQGIDHW-UHFFFAOYSA-N benzyl benzotriazole-1-carboxylate Chemical compound N1=NC2=CC=CC=C2N1C(=O)OCC1=CC=CC=C1 OEFZXDSNQGIDHW-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- FMCIMULCKWJTAW-UHFFFAOYSA-N ethyl 2-[[5-(6-chloropyridin-2-yl)-4-methyl-1,3-thiazol-2-yl]methoxy]acetate Chemical compound CCOC(COCC1=NC(C)=C(C2=NC(Cl)=CC=C2)S1)=O FMCIMULCKWJTAW-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019000 fluorine Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- STOAMTMWSCZXCB-UHFFFAOYSA-N methyl N-[[5-[2-(4,7-difluoro-2H-benzotriazol-5-yl)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]methyl]carbamate Chemical compound CC1=C(C2=CSC(C(C=C(C3=C4N=NN3)F)=C4F)=N2)SC(CNC(OC)=O)=N1 STOAMTMWSCZXCB-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- KFBLSJVVUQSKHS-UHFFFAOYSA-N tert-butyl-[[5-(6-chloropyridin-2-yl)-4-methyl-1,3-thiazol-2-yl]methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=NC(C)=C(C2=NC(Cl)=CC=C2)S1 KFBLSJVVUQSKHS-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GBLGZXXBHDQAEE-UHFFFAOYSA-N (5-bromo-4-methyl-1,3-thiazol-2-yl)methoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC(S1)=NC(C)=C1Br GBLGZXXBHDQAEE-UHFFFAOYSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- JLIRHKMBJHLGBA-UHFFFAOYSA-N 2,3,6-trifluoro-4-[4-[4-methyl-2-(pyridin-2-yloxymethyl)-1,3-thiazol-5-yl]-1,3-thiazol-2-yl]phenol Chemical compound CC1=C(C2=CSC(C(C=C(C(O)=C3F)F)=C3F)=N2)SC(COC2=NC=CC=C2)=N1 JLIRHKMBJHLGBA-UHFFFAOYSA-N 0.000 description 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- GKPHNZYMLJPYJJ-UHFFFAOYSA-N 2,3-difluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1F GKPHNZYMLJPYJJ-UHFFFAOYSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- APRMCBSTMFKLEI-UHFFFAOYSA-N 2-chloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1 APRMCBSTMFKLEI-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- KFTYFTKODBWKOU-UHFFFAOYSA-N 2-methylsulfonylethanol Chemical compound CS(=O)(=O)CCO KFTYFTKODBWKOU-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IBWYHNOFSKJKKY-UHFFFAOYSA-N 3-chloropyridazine Chemical compound ClC1=CC=CN=N1 IBWYHNOFSKJKKY-UHFFFAOYSA-N 0.000 description 1
- OHTJCFFZWLQPFX-UHFFFAOYSA-N 3-fluoro-2-hydroxy-5-[6-[4-methyl-2-(pyrimidin-2-yloxymethyl)-1,3-thiazol-5-yl]pyridin-2-yl]benzonitrile Chemical compound CC1=C(C2=CC=CC(C(C=C3F)=CC(C#N)=C3O)=N2)SC(COC2=NC=CC=N2)=N1 OHTJCFFZWLQPFX-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- UHBNTNAQHOUJIX-UHFFFAOYSA-N 4-(3-iodophenyl)-1,3-thiazole-5-carboxamide Chemical compound S1C=NC(C=2C=C(I)C=CC=2)=C1C(=O)N UHBNTNAQHOUJIX-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- RLLMWSAXEVXLHD-UHFFFAOYSA-N 5-[6-(4,7-difluoro-2H-benzotriazol-5-yl)pyridin-2-yl]-4-methyl-2-[(5-methylpyrimidin-2-yl)oxymethyl]-1,3-thiazole Chemical compound CC1=C(C2=NC(C(C=C(C3=C4NN=N3)F)=C4F)=CC=C2)SC(COC2=NC=C(C)C=N2)=N1 RLLMWSAXEVXLHD-UHFFFAOYSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- SQBQBUROKSTPFS-UHFFFAOYSA-N 6-bromo-4-fluoro-2H-benzotriazole Chemical compound Fc1cc(Br)cc2nn[nH]c12 SQBQBUROKSTPFS-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UPNVEVSJAXVLHC-UHFFFAOYSA-N C[Si](C)(C)CCOCN1N=NC(C(F)=C2)=C1C=C2Br Chemical compound C[Si](C)(C)CCOCN1N=NC(C(F)=C2)=C1C=C2Br UPNVEVSJAXVLHC-UHFFFAOYSA-N 0.000 description 1
- 101100231508 Caenorhabditis elegans ceh-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000594702 Homo sapiens Bisphosphoglycerate mutase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SHAMDXBZYTZRMT-UHFFFAOYSA-N N-(benzenesulfonyl)-4-(4-bromo-1,3-thiazol-2-yl)benzamide Chemical compound O=C(C(C=C1)=CC=C1C1=NC(Br)=CS1)NS(C1=CC=CC=C1)(=O)=O SHAMDXBZYTZRMT-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 229910017833 NH2NH2.H2O Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101100109871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aro-8 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HLNPDVKKRBWQAA-UHFFFAOYSA-M amino(trimethyl)azanium;iodide Chemical compound [I-].C[N+](C)(C)N HLNPDVKKRBWQAA-UHFFFAOYSA-M 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-O cyclohexylammonium Chemical compound [NH3+]C1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-O 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- CWHRHCATIKFSND-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron Chemical compound [Fe].ClCCl.Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 CWHRHCATIKFSND-UHFFFAOYSA-L 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TVQBEQOORXICPK-UHFFFAOYSA-N methyl N-[[5-[2-[4-(benzenesulfonylcarbamoyl)phenyl]-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]methyl]carbamate Chemical compound CC1=C(C2=CSC(C(C=C3)=CC=C3C(NS(C3=CC=CC=C3)(=O)=O)=O)=N2)SC(CNC(OC)=O)=N1 TVQBEQOORXICPK-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 229940094989 trimethylsilane Drugs 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Abstract
Provided herein are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
Description
COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE
TREATMENT OF SICKLE CELL DISEASE
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application daims the benefit under 35 U.S.C. §119(e) of United States Provisional Application No. 63/077,973, fïled September 14, 2020, which is hereby incorporated by reference in its entirety.
FIELD
[0002] The présent disclosure relates generally to compounds, compositions, and method for treating sickle cell disease.
BACKGROUND
[0003] Bis-phosphoglycerate mutase (BPGM) is an enzyme in the glucose metabolism pathway that régulâtes the levels of 2,3-bis-phosphoglycerate (2,3-BPG) inside the red blood cell (RBC). 2,3-BPG is a known allosteric modulator of hemoglobin that stabilizes the de-oxy or “T-State” of hemoglobin that has a tendency to polymerize, resulting in the sickle cell morphology. There is currently a large unmet medical need for safe and effective oral thérapies for the treatment of sickle cell disease. BPGM modulators that lower 2,3-BPG levels offer a novel mechanism of action from existing thérapies and may significantly reduce sickling in sickle cell disease patients.
[0004] Accordingly, in one aspect, provided herein are compounds which are modulators of BPGM for use in treating sickle cell disease.
SUMMARY
[0005] Described herein, in certain embodiments, are compounds and compositions thereof for modulating bis-phosphoglycerate mutase (BPGM) for treating sickle cell disease.
[0006] The following embodiments are encompassed.
[0007] Embodiment la is a compound of Formula (I):
(I) or a pharmaceutically acceptable sait thereof, wherein:
Ring A is a 5-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaiyl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-Ce alkyl, Ci-Ce haloalkyl, -CN,
-N(H)C(O)R6, -N(H)SO2R6, -SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently Ci-Ce alkyl, Ci-Ce haloalkyl, or halo;
each R3 is independently Ci-Ce alkyl, Ci-Ce haloalkyl, or Ca-Ce cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2Rs, 5- to 6-membered heteroaryl or heterocyclyl, or -C(0)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups; .
m is 0-4;
n is 0-2;
o is 0-2;
R5 is phenyl or Ci-Cô alkyl;
X is -CR6R7- or a bond;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or Ci-Cô alkyl;
Z is Z1 or Z2;
Z* is H, Ci-C6 alkyl, -C(O)(Ci-C6 alkyl), -CO2(Ci-C6 alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C6 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(Ci-C6 alkylene)NR6R7, -NR6C(O)(Ci-C6 alkyl), -NR6R7, -(Ci-C6 alkyl)-CO2H, -(Ci-C6 alkyl)-OH, or -C(NR6R7)=N-CN, wherein Ci-Cô alkylene is optionally substituted by 1-6 halo, Ci-Ce alkyl, or
Ci-Ce haloalkyl;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl), -CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl, -C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8;
each R8 is independently halo, Ci-Cô alkyl, Ci-Ce haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(Ci-C6 alkyl), -CH2-O(Ci-C6 alkyl),' or -(Ci-C6 alkyl)-OH.
[0008] Embodiment 1b is a compound of Formula (I):
(I) or a pharmaceutically acceptable sait thereof, wherein:
Ring A is a 5-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-Ce alkyl, Ci-Ce haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-N(H)SO2(C6H5), -SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently Ci-Ce alkyl, Ci-Ce haloalkyl, or halo;
each R3 is independently Ci-Ce alkyl, Ci-Ce haloalkyl, or C3-C6 cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is 0-4;
n , is 0-2;
o is 0-2;
R5 is phenyl or Ci-Ce alkyl;
X is -CR6R7- or a bond;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or Ci-Cô alkyl;
Z is Z1 or Z2;
Z1 is H, Ci-C6 alkyl, -C(O)(Ci-C6 alkyl), -CO2(Ci-C6 alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C6 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(Ci-C6 alkylene)NR6R7, -NR6C(O)(Ci-C6 alkyl), -NR6R7, . -(Ci-C6 alkyl)-CO2H, -(Ci-C6 alkyl)-OH, or -C(NR6R7)=N-CN, wherein Ci-Ce alkylene is optionally substituted by 1-6 halo, Ci-Cô alkyl, or Ci-Ce haloalkyl;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
- CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
- C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8;
each R8 is independently halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -NR6R7, -OH, oxo, -CO2H,
- O(Ci-C6 alkyl), -CH2-O(Ci-C6 alkyl), or -(Ci-C6 alkyl)-OH.
[0009] Embodiment 2 is the compound of embodiment 1, or a pharmaceutically acceptable sait thereof, wherein:
Ring A is thiazolylene.
[0010] Embodiment 3 is the compound of embodiment 1 or 2, or a pharmaceutically acceptable sait thereof, wherein:
each R3 is independently C1-C3 alkyl or C3-C6 cycloalkyl.
[0011] Embodiment 4 is the compound of embodiment 3, or a pharmaceutically acceptable sait thereof, wherein:
each R3 is independently -CH3 or cyclopropyl.
[0012] Embodiment 5 is the compound of any one of embodiments 1-4, or a pharmaceutically acceptable sait thereof, wherein:
o is 0 or 1.
[0013] Embodiment 6 is the compound of any one of embodiments 1-5, or a pharmaceutically acceptable sait thereof, wherein:
Ring B is phenylene, pyridinylene, thiazolylene, pyrazolylene, pyrimidinylene, or thienylene. [0014] Embodiment 7 is the compound of any one of embodiments 1-6, or a pharmaceutically acceptable sait thereof, wherein:
each R2 is independently C1-C3 alkyl or halo.
[0015] Embodiment 8 is the compound of any one of embodiments 1-7, or a pharmaceutically acceptable sait thereof, wherein:
n isOorl.
[0016] Embodiment 9 is the compound of any one of embodiments 1-8, or a pharmaceutically acceptable sait thereof, wherein:
Ring C is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected ' from N and O, a 5- to 6-membered heteroaiyl containing 1-4 nitrogen atoms, or phenyl substituted by one R4.
[0017] Embodiment 10 is the compound of any one of embodiments 1-9, or a pharmaceutically acceptable sait thereof, wherein:
R4 is -OH, -OP(O)(OH)z, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups; and
R5 is phenyl or C1-C3 alkyl.
[0018] Embodiment 11 is the compound of any one of embodiments 1-10, or a pharmaceutically acceptable sait thereof, wherein Ring C-(R’)m is selected from
[0019] Embodiment 12a is the compound of any one of embodiments 1-11, or a pharmaceutically acceptable sait thereof, wherein:
each R1 is independently -OH, halo, oxo, C1-C3 alkyl, C1-C3 haloalkyl, -CN, .
-N(H)C(O)R6, -N(H)SO2R6,-SO2NR6R7, or -C(O)N(H)SO2R6; and each R6 and R7 is independently H or C1-C3 alkyl.
[0020] Embodiment 12b is the compound of any one of embodiments 1-11, or a pharmaceutically acceptable sait thereof, wherein:
each R1 is independently -OH, halo, oxo, C1-C3 alkyl, C1-C3 haloalkyl, -CN,
-N(H)C(O)R6, -N(H)SO2R6,-N(H)SO2(C6H5), -SO2NR6R7, or -C(O)N(H)SO2R6; and
[0021] each R6 and R7 is independently H or C1-C3 alkyl.
[0022] Embodiment 13 is the compound of embodiment 12, or a pharmaceutically acceptable sait thereof, wherein:
each R1 is independently -OH, F, oxo, -CH3, -CN, -N(H)C(O)CH3, -N(H)SO2(CeH5), -N(H)SO2CH3. -SO2NH2, or -C(O)N(H)SO2CH3..
[0023] Embodiment 14 is the compound of any one of embodiments 1-13, or a pharmaceutically acceptable sait thereof, wherein:
m is 0-3.
[0024] Embodiment 15 is the compound of any one of embodiments 1-14, or a pharmaceutically acceptable sait thereof, wherein:
X is -CR6R7-.
[0025] Embodiment 16 is the compound of embodiment 15, or a pharmaceutically acceptable sait thereof, wherein:
R6 and R7 are each H.
[0026] Embodiment 17 is the compound of any one of embodiments 1-14, or a pharmaceutically acceptable sait thereof, wherein:
X is a bond.
[0027] Embodiment 18 is the compound of any one of embodiments 1-17, or a pharmaceutically acceptable sait thereof, wherein:
Y is -O-.
[0028] Embodiment 19 is the compound of any one of embodiments 1-17, or a pharmaceutically acceptable sait thereof, wherein:
Y is -N(H)- or a bond.
[0029] Embodiment 20 is the compound of any one of embodiments 1-19, or a pharmaceutically acceptable sait thereof, wherein:
Z is Z1.
[0030] Embodiment 21 is the compound of embodiment 20, or a pharmaceutically acceptable sait thereof, wherein:
Z1 is H, C1-C3 alkyl, -C(O)(Ci-C3 alkyl), -CO2(Ci-C3 alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C3 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(Ci-C3 alkylene)NR6R7, -NR6C(O)(Ci-C3 alkyl), -NR6R7, -(Ci-C3 alkyl)-CO2H, -(Ci-C3 alkyl)-OH, or -C(NR6R7)=N-CN, wherein Ci-C3 alkylene is optionally substituted by 1-2 halo, Ci-C3 alkyl, or Ci-C3haloalkyl; and ·, each R6 and R7 is independently H or Ci-C3 alkyl.
[0031] Embodiment 22 is the compound of embodiment 20 or 21, or a pharmaceutically acceptable sait thereof, wherein:
Z1 is H, -CO2CH3, -CO2C(CH3)3, -C(O)CH3, -C(O)C(CH3)3, -C(N(CH3)2)=N-CN, -C(O)N(CH3)2, -CH3, -CH2CH3, -CH2C(CH3)3, -CH2CO2H, -CH2C(CH3)2OH, -C(O)N(CH3)CH2CH2N(CH3)2, -CH2C(O)N(CH3)2, -CH(CH3)C(O)N(CH3)2, -N(CH3)2, -N(CH3)C(O)CH3, or -C(O)CH(CH3)CH2N(CH3)2.
[0032] Embodiment 23 is the compound of any one of embodiments 1-19, or a pharmaceutically acceptable sait thereof, wherein:
Z is Z2.
[0033] Embodiment 24 is the compound of embodiment 23, or a pharmaceutically acceptable sait thereof, wherein:
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
-CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl, -C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-2 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8.
[0034] Embodiment 25 is the compound of embodiment 23 or 24, or a pharmaceutically acceptable sait thereof, wherein:
Z2 is pyrimidinyl, pyridazinyl, pyrrolidinyl, piperidinyl, pyridazinyl,
-C(O)(tetrahydropyranyl), -C(O)(pyrrolidinyl), -C(O)(pyridazinyl), -C(O)(piperidinyl), -C(O)(azetidinyl), -C(O)(pyrazolyl), -C(O)(piperazinyl), -CH2C(O)(pyrrolidinyl), -CH2C(O)(piperidinyl), or -CH2C(O)(piperazinyl), wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8.
[0035] Embodiment 26 is the compound of any one of embodiments 1-19 and 23-25, or a pharmaceutically acceptable sait thereof, wherein:
each R8 is independently halo, C1-C3 alkyl, C1-C3 haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(Ci-C3 alkyl), -CH2-O(Ci-C3 alkyl), or-(Ci-C3 alkyl)-OH; and each R6 and R7 is independently H or C1-C3 alkyl.
[0036] Embodiment 27 is the compound of embodiment 26, or a pharmaceutically acceptable sait thereof, wherein:
each R8 is independently -CH3, -CH2CH3, -NH2, -OH, oxo, -N(CH3)2, -OCH3, -CH2OCH3,
-CF3, -CH2CH2OH, -CO2H, or Cl.
[0037] Embodiment 28 is the compound of any one of embodiments 1-22, or a pharmaceutically acceptable sait thereof, wherein:
Z-Y-X- is
-CH2OH
-OCH2CH3 , or -CH2OCH3
[0038] Embodiment 29 is the compound of any one of embodiments 1-19 and 23-27, or a pharmaceutically acceptable sait thereof, wherein:
Z-Y-X- is
HO
[0039] Embodiment 30 is a compound selected from the compounds in Table 1, or a pharmaceutically acceptable sait thereof.
[0040] Embodiment 31 is a compound selected from the compounds in Table 2, or a pharmaceutically acceptable sait thereof.
[0041] Embodiment 32 is a pharmaceutical composition comprising the compound of any one of embodiments 1-31, or a pharmaceutically acceptable sait thereof, and at least one pharmaceutically acceptable excipient.
[0042] Embodiment 33 is a method of modulating bis-phosphoglycerate mutase (BPGM) comprising
- contacting an effective amount of the compound of any one of embodiments 1-31, or a pharmaceutically 10 acceptable sait thereof, or the pharmaceutical composition of embodiment 32, with the BPGM.
[0043] Embodiment 34 is a method of treating sickle cell disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of any one of embodiments 1-31, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of embodiment 32.
DETAILED DESCRIPTION
Définitions
[0044] Unless defined otherwise, ail technical and scientific terms used herein hâve the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailed description are exemplary
and explanatory only and are not restrictive of any subject matter claimed. To the extent any material incorporated herein by reference is inconsistent with the express content of this disclosure, the express content Controls. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the spécification and the appended daims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictâtes otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting. [0045] Reference in the spécification to “some embodiments”, “an embodiment”, “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily ail embodiments, of the disclosure.
[0046] As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. Hence “about 5 pL” means “about 5 pL” and also “5 pL.” Generally, the term “about” includes an amount that would be expected to be within experimental error, 15 such as for example, within 15%, 10%, or 5%.
[0047] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0048] “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1-C20 alkyl), 1 to 10 carbon atoms (i.e., C1-C10 alkyl), 1 to 6 carbon atoms (i.e., Ci-Cô alkyl) or 1 to 3 carbon atoms (i.e., C1-C3 alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl and 3-methylpentyl. When an alkyl residue having a spécifie number of carbons is named by Chemical name or identified by molecular formula, ail positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., -(CH2)3CH3), isobutyl (i.e., -CH2CH(CH3)2), sec-butyl (i.e., -CH(CH3)CH2CH3), and tert-butyl (i.e., -C(CH3)3); and “propyl” includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).
[0049] “Alkyl-OH” refers to an refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a hydroxyl (-OH). For example, “(Ci-Cô alkyl)OH” refers to a Ci-Ce alkyl which is substituted by one or more hydroxyl groups. A Ci alkyl-OH refers to a methyl group that may be substituted by 1-3 hydroxyl groups, a C2 alkyl-OH refers to an ethyl group that may be substituted by 1-5 hydroxyl groups, a C3 alkyl-OH refers to a propyl group that may be substituted by 1-7 hydroxyl groups, etc. Examples of alkyl-OH include -CH2OH, -CH2CH2OH, CH2CH(OH)CH2(OH), and the like.
[0050] “Alkyl-CCbH” refers to an refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a carboxylic acid (-CO2H). For example, “(Ci-Ce alkylj-CChH” refers to a Ci-Cô alkyl which is substituted by one or more carboxylic acid groups. A Ci alkyl-CChH refers to a methyl group that may be substituted by 1-3 carboxylic acid groups, a C2 alkylCO2H refers to an ethyl group that may be substituted by 1-5 carboxylic acid groups, a C3 alkyl-CCLH refers to a propyl group that may be substituted by 1-7 carboxylic acid groups, etc. Examples of alkyl CO2H include -CH2CO2H, -CH2CH2CO2H,
-CH2CH(CO2H)CH3, -CH2CH(CO2H)CH2CO2H, and the like.
[0051] “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, “Ci-Cô haloalkyl” refers to a Ci-Cô alkyl which is substituted by one or more halogen atoms. A Ci haloalkyl refers to a methyl group that may be substituted by 1-3 halo groups, a C2 haloalkyl refers to an ethyl group that may be substituted by 1-5 halo groups, a C3 haloalkyl refers to a propyl group that may be substituted by 1-7 halo groups, etc. Examples of haloalkyl include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. A haloalkyl may contain one or more halo atoms that are the same (i.e., ail fluoro) or a mixture of halo atoms (i.e, chloro and fluoro).
[0052] “Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged and spiro ring Systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-C20 cycloalkyl), 3 to 10 ring carbon atoms (i.e., C3-C10 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-C6 cycloalkyl). Cycloalkyl also includes “spiro cycloalkyl” when there are two positions for substitution on the same carbon atom. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbomyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl and the like. Further, the term cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachaient to the remainder of the molécule.
[0053] “Halogen” or “halo” includes fluoro, chloro, bromo, and iodo.
[0054] “Oxo” refers to the atom (=O) or (O).
[0055] “Heteroaryl” refers to an aromatic group (e.g., a 5-14 membered ring System) having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. As used herein, heteroaryl includes 1 to 10 ring carbon atoms and 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur within the ring. Examples of heteroaryl groups include pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl,
quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thîazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl and thiophenyl (i.e., thienyl). A heteroaryl may comprise one or more Noxide (N-O-) moieties, such as pyridine-N-oxide.
[0056] “Heterocyclyl” refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The term “heterocyclyl” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridgedheterocyclyl groups, fused-heterocyclyl groups and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged or spiro, and may comprise one or more oxo (C=O) or N-oxide (N-O-) moieties. Any non-aromatic ring containing at least one heteroatom is considered a heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to an aiyl or heteroaryl ring, regardless of the attachment to the remainder of the molécule. As used herein, heterocyclyl has 1 to 10 ring carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms, and 1 to 5 ring heteroatoms, 1 to 4 heteroatoms, 1 to 3 heteroatoms, or 1 to 2 heteroatoms independently selected from nitrogen, sulfur and oxygen. Examples of heterocyclyl groups include dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, 1 -oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl.
[0057] Certain commonly used alternative Chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “phenyl” group, a divalent “heteroaryl” group, a divalent “heterocyclyl” group etc., may also be referred to as an “alkylene” group, an “phenylene” group, 25 a “heteroarylene” group, or a “heterocyclylene” group, respectively.
[0058] The terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
[0059] Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Similarly, the above définitions are not intended to include
impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan.
[0060] Any compound or Formula described herein is intended to represent unlabeled forms as well as 5 isotopically labeled forms of the compounds. Isotopically labeled compounds hâve structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine and iodine, such as 2H, 3H, nC, 13C, 14C, 13N, I5N, I50,170,180,31P, 32P, 35S, 18F, 36C1,123I and 125I, respectively. Various 10 isotopically labeled compounds of the présent disclosure, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are included in this disclosure. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, détection or imaging techniques, such as positron émission tomography (PET) or single-photon émission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
[0061] The disclosure also includes “deuterated analogs” of compounds described herein in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molécule. Such compounds exhibit increased résistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends
Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens hâve been replaced by deuterium.
[0062] “Pharmaceutically acceptable” refers to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary 25 or human pharmaceutical use.
[0063] The terni “pharmaceutically acceptable sait” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition sait, 30 the free base can be obtained by basifying a solution of the acid sait. Conversely, if the product is a free base, an addition sait, particularly a pharmaceutically acceptable addition sait, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic méthodologies that may be used to préparé nontoxic pharmaceutically
acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnésium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines. Spécifie examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, Nethylpiperidine and the like.
[0064] The compounds disclosed herein, or their pharmaceutically acceptable salts, may include an 15 asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The disclosure is meant to include ali such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a sait or dérivative) using, for example, chiral high pressure liquid chromatography (HPLC).
[0065] “Tautomer” refers to altemate forms of a compound that differ in the position of a proton, such 25 as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring -NH-moiety and a ring=N moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. Ail tautomeric forms of the compounds described herein are intended to be included.
[0066] A “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds ‘ 30 but having different three-dimensional structures, which are not interchangeable. The présent disclosure contemplâtes various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molécules are nonsuperimposable mirror images of one another.
[0067] “Diastereoisomers” are stereoisomers that hâve at least two asymmetric atoms, but which are not mirror-images of each other.
[0068] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” or “excipient” includes any and ail solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonie and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except irisofar as any conventional media or agent is incompatible with the active ingrédient, its use in the therapeutic compositions is contemplated. Supplementary active ingrédients can also be incorporated into the compositions.
[0069] “Effective amount” or dose of a compound or a composition refers to that amount of the compound or the composition that results in an intended resuit as desired based on the disclosure herein. Effective amounts can be determined by standard pharmaceutical procedures in cell cultures or experimental animais including, without limitation, by determining the LD50 (the dose léthal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
[0070] “Therapeutically effective amount” or dose of a compound or a compositions refers to that amount of the compound or the composition that results in réduction or inhibition of symptoms or a prolongation of survival in a subject (i.e., a human patient). The results may require multiple doses of the 15 compound or the composition.
[0071] “Treating” or “treatment” of a disease in a subject refers to 1) preventing the disease from occurring in a patient that is predisposed or does not yet display symptoms of the disease; 2) inhibiting the disease or arresting its development; or 3) ameliorating or causing régression of the disease. As used herein, “treatment” or “treating” is an approach for obtaining bénéficiai or desired results including clinical results. For the purposes of this disclosures, bénéficiai or desired results include, but are not limited to, one or more of the following: decreasing one or more symptoms resulting from the disease or disorder, diminishing the extent of the disease or disorder, stabilizing the disease or disorder (e.g., preventing or delaying the worsening of the disease or disorder), delaying the occurrence or récurrence of the disease or disorder, delay or slowing the progression of the disease or disorder, ameliorating the disease or disorder State, providing a remission (whether partial or total) of the disease or disorder, decreasing the dose of one or more other médications required to treat the disease or disorder, enhancing 4 the effect of another médication used to treat the disease or disorder, delaying the progression of the disease or disorder, increasing the quality of life, and/or prolonging survival of a subject. Also encompassed by “treatment” is a réduction of pathological conséquence of the disease or disorder. The 30 methods of the disclosure contemplate any one or more of these aspects of treatment.
[0072] As used herein, the terms “individual(s)”, “subject(s)” and “patient(s)” mean any mammal. Examples include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, the mammal is a human.
[0073] Although various features of the disclosure may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the disclosure may be described herein in the context of separate embodiments for clarity, the disclosure may also be implemented in a single embodiment.
Compounds
[0074] In one aspect, provided herein is a compound of Formula (I):
or a pharmaceutically acceptable sait thereof, wherein:
Ring A is a 5-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
' Ring B is phenylene or a 5- to 6-membered heteroarylefte containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-Cô alkyl, Ci-Cô haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-N(H)SO2(C6H5), -SO2NR6R7, or-C(O)N(H)SO2R6;
each R2 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or halo;
each R3 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or Cj-Cô cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is0-4;
n is0-2;
o is0-2;
R5 is phenyl or Ci-Cô alkyl;
X is -CR6R7- or a bond;
Y is -O-, -N(H)-, or a bond;· each R6 and R7 is independently H or Ci-Cô alkyl;
Z isZ’orZ2;
Z1 is H, Ci-C6 alkyl, -C(O)(Ci-C6 alkyl), -CO2(Ci-C6 alkyl), -C(O)NR6R7,
-C(O)NR6(Ci-C6 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7,
-C(O)(Ci-C6 alkylene)NR6R7, -NR6C(O)(Ci-C6 alkyl), -NR6R7,
- (Ci-Cô alkyl)-CO2H, -(Ci-C6 alkyl)-OH, or-C(NR6R7)=N-CN, wherein Ci-Cô alkylene is optionally substituted by 1-6 halo, Ci-Cô alkyl, or Ci-Cô haloalkyl;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
- CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
- C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8;
each R8 is independently halo, Ci-Cô alkyl, Ci-Cô haloalkyl, -NR6R7, -OH, oxo, -CO2H,
- O(C,-Cô alkyl), -CH2-O(Ci-C6 alkyl), or -(Ci-C6 alkyl)-OH.
[0075] Provided herein is a compound of Formula (I-a):
or a pharmaceutically acceptable sait thereof, wherein:
Ring A is thiazolylene;
Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-Cô alkyl, Ci-Cô haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6.-SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or halo;
each R3 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or Cs-Ce cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaiyl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1 -2 oxo groups;
m is 0-4;
is 0-2;
o is 0-2;
R5 is phenyl or Ci-Ce alkyl;
X is -CR6R7-;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or Ci-Cô alkyl;
Z is Z2;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
- CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
- C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heteroeyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8; and each R8 is independently halo, Ci-Cô alkyl, Ci-Cô haloalkyl, -NR6R7, -OH, oxo, -CO2H,
- O(Ci-C6 alkyl), -CH2-O(Ci-C6 alkyl), or -(Ci-C6 alkyl)-OH.
[0076] Provided herein is a compound of Formula (I-al):
or a pharmaceutically acceptable sait thereof, wherein:
Ring A is thiazolylene;
Ring B is a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-Cô alkyl, Ci-Cô haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-SO2NR6R7, or-C(O)N(H)SO2R6;
each R2 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or halo;
each R3 is independently Ci-Cô alkyl, Ci-Cô haloalkyl, or C3-C6 cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is0-4;
n is0-2;
o is0-2;
R5 is phenyl or Ci-Ce alkyl;
X is -CR6R7-;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or Ci-Ce alkyl;
Z is Z2;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl), -CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl, -C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaiyl and heterocyclyl are optionally substituted by 1-3 R8; and each R8 is independently halo, Ci-Ce alkyl, Ci-Cô haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(Ci-C6 alkyl), -CH2-O(Ci-C6 alkyl), or -(Ci-C6 alkyl)-OH.
[0077] In some embodiments, Ring A is a 5-membered heteroarylene containing 1-3 heteroatoms selected from N and S. In some embodiments, Ring A is a 5-membered heteroarylene containing 1-2 heteroatoms selected from N and S. In some embodiments, Ring A is a 5-membered heteroarylene containing 1 heteroatom selected from N and S. In some embodiments, Ring A is a 5-membered heteroaiylene containing 2 heteroatoms selected from N and S. In some embodiments, Ring A is a 5membered heteroarylene containing one nitrogen atoms and one sulfur atom. In some embodiments, Ring A is thiazolylene.
[0078] In some embodiments, each R3 is independently Ci-Cô alkyl, Ci-Ce haloalkyl, or C3-C6 cycloalkyl. In some embodiments, each R3 is independently C1-C3 alkyl or C3-C6 cycloalkyl. In some embodiments, R3 is methyl, ethyl, or propyl. In some embodiments, R3 is methyl. In some embodiments, R3 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R3 is cyclopropyl. In some embodiments, each R3 is independently -CH3 or cyclopropyl.
[0079] In some embodiments, o is 0-2. In some embodiments, o is 1-2. In some embodiments, o is 0 or 1. In some embodiments, o is 0. In some embodiments, o is 1. In some embodiments, o is 2.
[0080] In some embodiments, Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S. In some embodiments, Ring B is phenylene. In some embodiments, Ring B is a 5- to 6-membered heteroaiylene containing 1-3 heteroatoms selected from N and S. In some embodiments, Ring B is a 5- to 6-membered heteroarylene containing 1-2 heteroatoms selected from N and S. In some embodiments, Ring B is phenylene, pyridinylene, thiazolylene, pyrazolylene, pyrimidinylene, or thienylene.
[0081] In some embodiments, each R2 is independently Ci-Ce alkyl, Ci-Ce haloalkyl, or halo. In some embodiments, each R2 is independently C1-C3 alkyl or halo. In some embodiments, R2 is methyl, ethyl, or propyl. In some embodiments, R2 is methyl. In some embodiments, R2 is F, Cl, or Br.
[0082] In some embodiments, n is 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is
0. In some embodiments, n is 1. In some embodiments, n is 2.
[0083] In some embodiments, Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4. In some embodiments, Ring C is a fiised bicyclic 9-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4. In some embodiments, Ring C is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O. In some embodiments, Ring C is a fused bicyclic 9-membered heteroaryl containing 1-4 heteroatoms selected from N and O. In some embodiments, Ring C is a fused bicyclic 9-membered heterocyclyl containing 1-4 heteroatoms selected from N and O. In some embodiments, one ring of the fused bicyclic heteroaryl or heterocyclyl is substituted by 0-4 R1 groups. In some embodiments, both rings of the fused bicyclic heteroaryl or heterocyclyl are together substituted by 0-4 R1 groups. In some embodiments, Ring C is a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms. In some embodiments, Ring C is a 5-membered heteroaryl containing 1-4 nitrogen atoms. In some embodiments, Ring C is a 6-membered heteroaryl containing 1-4 nitrogen atoms. In some embodiments, Ring C is phenyl substituted by one R4.
[0084] In some embodiments, R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups. In some embodiments, R4 is -OH. In some embodiments, R4 is -OP(O)(OH)2. In some embodiments, R4 is -NO2. In some embodiments, R4 is C(O)N(H)SO2R5. In some embodiments, R4 is 5- to 6-membered heteroaryl or heterocyclyl, wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups. In some embodiments, R4 is 5- to 6-membered heteroaryl containing 1-4 heteroatoms selected from N, O, and S. In some embodiments, R4 is 5- to 630 membered heterocyclyl containing 1-4 heteroatoms selected from N, O, and S, and optionally substituted by 1-2 oxo groups. In some embodiments, R4 is -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups. In some embodiments, R4 is C(O)N(H)-(5- to 6-membered heteroaryl), wherein the heteroaryl contains 1-4 heteroatoms selected from
N, O, and S. In some embodiments, R4 is -C(O)N(H)-(5- to 6-membered heterocyclyl), wherein the heterocyclyl contains 1-4 heteroatoms selected from N, O, and S, and is optionally substituted by 1-2 oxo groups. In some embodiments, R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups. In any of these variations, R5 is phenyl or Ci-Ce alkyl. In some embodiments, R5 is phenyl or C1-C3 alkyl.
[0085] In some embodiments, Ring C-(R')m is selected from
[0086] As shown above, certain nitrogen atoms of the heteroaryl and heterocyclyl rings are represented as -NH- in order to complété the valency. However, it is understood that the -NH- group may also be substituted by R1 (-NR1-). It is also understood that when -(R1)™ is drawn through a fused bicyclic heteroaryl or heterocyclyl, then one or both of the fused rings may be substituted by R1 groups. In some embodiments, only one ring of the fused bicyclic ring is substituted by R1 groups. In some embodiments, both rings of the fused bicyclic ring are substituted by R1 groups, such that the total number of R1 groups substituting the bicyclic ring is 0-4.
[0087] In some embodiments, each R1 is independently -OH, halo, oxo, Ci-Cô alkyl, Ci-Cô haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-N(H)SO2(CôH5), -SO2NR6R7, or -C(O)N(H)SO2R6. In some embodiments, each R1 is independently -OH, halo, oxo, Ci-Cô alkyl, Ci-Cô haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6.-SO2NR6R7, or -C(O)N(H)SO2R6. In some embodiments, each R1 is independently -OH, halo, oxo, C1-C3 alkyl, C1-C3 haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-SO2NR6R7, or -C(O)N(H)SO2R6.
[0088] In some embodiments, R1 is -OH. In some embodiments, R1 is halo. In some embodiments, R1 is F, Cl, or Br. In some embodiments, R1 is oxo. In some embodiments, R1 is Ci-Cô alkyl. In some embodiments, R1 is C1-C3 alkyl. In some embodiments, R1 is methyl, ethyl, or propyl. In some embodiments, R1 is Ci-Cô haloalkyl. In some embodiments, R1 is C1-C3 haloalkyl. In some embodiments, R1 is -CN. In some embodiments, R1 is -N(H)C(O)R6. In some embodiments, R1 is -N(H)SO2R6. In some embodiments, R1 is-SO2NR6R7. In some embodiments, R1 is -C(O)N(H)SO2R6. In some embodiments, each R1 is independently -OH, halo, oxo, C1-C3 alkyl, C1-C3 haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6, -SO2NR6R7, or -C(O)N(H)SO2R6. In any of these variations, each R6 and R7 is independently H or Ci-Cô alkyl. In some embodiments, each R6 and R7 is independently H or C1-C3 alkyl. In some embodiments, each R1 is independently -OH, F, oxo, -CH3, -CN, -N(H)C(O)CH3, -N(H)SO2(C6H5), -N(H)SO2CH3, -SO2NH2, or-C(O)N(H)SO2CH3.
[0089] In some embodiments, m is 0-4. In some embodiments, m is 0-3. In some embodiments, m is 0. In some embodiments, m is 1-3. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
[0090] In some embodiments, R5 is phenyl or Ci-Cô alkyl. In some embodiments, R5 is phenyl or CiC3 alkyl. In some embodiments, R5 is phenyl. In some embodiments, R5 is Ci-Cô alkyl. In some embodiments, R5 is C1-C3 alkyl. In some embodiments, R5 is methyl, ethyl, or propyl. In some embodiments, R5 is methyl. In some embodiments, R5 is phenyl or methyl. .
[0091] In some embodiments, X is -CR6R7- or a bond. In some embodiments, X is -CR6R7-. In some variations, R6 and R7 are independently H or Ci-Cô alkyl. In some variations, R6 and R7 are each H, and X is -CH2-. In some embodiments, X is a bond.
[0092] In some embodiments, Y is -O-, -N(H)-, or a bond. In some embodiments, Y is -O-. In some embodiments, Y is -N(H)-. In some embodiments, Y is a bond.
[0093] In some embodiments, each R6 and R7 is independently H or Ci-Ce alkyl. In some embodiments, each R6 and R7 is independently H or C1-C3 alkyl. In some embodiments, R6 and R7 are each H. In some embodiments, R6 is H. In some embodiments, R7 is H. In some embodiments, R6 is CiCô alkyl. In some embodiments, R7 is Ci-Cô alkyl. In some embodiments, R6 is H and R7 is Ci-Cô alkyl. In some embodiments, R6 is H and R7 is C1-C3 alkyl. In some embodiments, R6 and R7 are each independently Ci-Cô alkyl. In some embodiments, R6 and R7 are each independently C1-C3 alkyl. In some embodiments, R6 and R7 are each independently methyl, ethyl, or propyl. In some embodiments, R6 and R7 are each methyl.
[0094] In some embodiments, Z is Z1.
[0095] In some embodiments, Z1 is H, Ci-Cô alkyl, -C(O)(Ci-Cô alkyl), -CO2(Ci-Cô alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C6 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(Ci-C6 alkylene)NR6R7, -NR6C(O)(Ci-C6 alkyl), -NR6R7, -(Ci-C6 alkyl)-CO2H, -(Ci-C6 alkyl)-OH, or -C(NR6R7)=N-CN. In any of these variations, Ci-Cô alkylene is optionally substituted by 1-6 halo, CiCô alkyl, or Ci-Côhaloalkyl. In some embodiments, Z'is H, C1-C3 alkyl, -C(O)(Ci-C3 alkyl), -CO2(Ci-C3 alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C3 alkylene)NR6R7,
-CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(Ci-C3 alkylene)NR6R7, -NR6C(O)(Ci-C3 alkyl), -NR6R7, -(C1-C3 alkyl)-CO2H, or -(C1-C3 alkyl)-OH, or -C(NR6R7)=N-CN. In any of these variations, CiC3 alkylene is optionally substituted by 1-2 halo, C1-C3 alkyl, or C1-C3 haloalkyl. In some embodiments, each R6 and R7 is independently H or C1-C3 alkyl. In some embodiments, Z1 is H, -CO2CH3, -CO2C(CH3)3, -C(O)CH3, -C(O)C(CH3)3, -C(N(CH3)2)=N-CN,
-C(O)N(CH3)2, -CH3, -CH2CH3, -CH2C(CH3)3, -CH2CO2H, -CH2C(CH3)2OH, -C(O)N(CH3)CH2CH2N(CH3)2, -CH2C(O)N(CH3)2, -CH(CH3)C(O)N(CH3)2, -N(CH3)2, -N(CH3)C(O)CH3, or -C(O)CH(CH3)CH2N(CH3)2. *
[0096] In some embodiments, if X is a bond and Y is a bond; and Z'is not hydrogen.
[0097] In some embodiments, Z is Z2.
[0098] In some embodiments, Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl), -CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl, -C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8. In some embodiments, Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6membered heteroaryl), -CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl, -C(O)(4to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-2 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8. In some embodiments, Z2 is pyrimidinyl, pyridazinyl, pyrrolidinyl, piperidinyl, pyridazinyl, -C(O)(tetrahydropyranyl), -C(O)(pyrrolidinyl), -C(O)(pyridazinyl),
-C(O)(piperidinyl), -C(O)(azetidinyl), -C(0)(pyrazolyl), -C(O)(piperazinyl), -CH2C(O)(pyrrolidinyl), -CH2C(O)(piperidinyl), or -CH2C(O)(piperazinyl), wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8.
[0099] In some embodiments, each R8 is independently halo, Ci-Ce alkyl, Ci-Ce haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(Ci-C6 alkyl), -CH2-O(Ci-C6 alkyl), or -(Ci-C6 alkyl)-OH. In some embodiments, each R8 is independently halo, C1-C3 alkyl, C1-C3 haloalkyl, -NR6R7, -OH, oxo, -CO2H, O(Ci-C3 alkyl), -CH2-O(Ci-C3 alkyl), or -(C1-C3 alkyl)-OH. In some variations, each R6 and R7 is independently H or C1-C3 alkyl. In some embodiments, each R8 is independently -CH3, -CH2CH3, -NH2, OH, oxo, -N(CH3)2, -OCH3, -CH2OCH3, -CF3, -CH2CH2OH, -CO2H, or Cl.
[0100] In some embodiments, Z-Y-X- is
[0102] In some embodiments, the compound of Formula (I) is a compound of Formula (II), (III), (IV), (V), or(VI):
(V) (VI) wherein R1, m, R2, n, R3, ο, X, Y, and Z are as described for Formula (I).
[0103] In some embodiments, the compound of Formula (I) is a compound of Formula (II), wherein R’, m, R2, n, R3, ο, X, Y, and Z are as described for Formula (I). In some embodiments, the compound of Formula (I) is a compound of Formula (III), wherein R1, m, R2, n, R3, ο, X, Y, and Z are as described for Formula (I). In some embodiments, the compound of Formula (I) is a compound of Formula (IV), wherein R1, m, R2, n, R3, ο, X, Y, and Z are as described for Formula (I). In some embodiments, the compound of Formula (I) is a compound of Formula (V), wherein R1, m, R , n, R3, ο, X, Y, and Z are as described for Formula (I). In some embodiments, the compound of Formula (VI) is a compound of Formula (Π), wherein R1, m, R2, n, R3, ο, X, Y, and Z are as described for Formula (I).
[0104] In some embodiments, the compound is of Formula (II)-(VI) and X is -CH2-. In some embodiments, the compound is of Formula (II)-(VI) and Y is -O- or -N(H)-. In some embodiments, the compound is of Formula (II)-(VI) and R1 is halo (such as fluoro), -CN, or -OH, and m is 1, 2, or 3. In some embodiments, the compound is of Formula (II)-(VI) and o is 0. In some embodiments, the compound is of Formula (II)-(VI) and o is 1. In some embodiments, the compound is of Formula (Π)(VI) and n is 0. In some embodiments, the compound is of Formula (II)-(VI) and R3 is Ci-Cô alkyl (such as methyl), and o is 1. In some embodiments, the compound is of Formula (II)-(VI) and Z is 6-membered •heteroaryl (such as pyridazinyl, pyrimidinyl, or pyridinyl) optionally substituted by Ci-Cô alkyl (such as methyl). In some embodiments, the compound is of Formula (II)-(VI) and Z is -CChiCi-Ce alkyl) (such as -CO2CH3) or -(Ci-Cô alkyl)-OH (such as -CH2C(CH3)2OH). In some embodiments, the compound is of Formula (II)-(VI) and R4 is -OH or 6-membered heteroaryl or heterocyclyl (such as tetrazolyl).
[0105] In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (II), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl, -CO2(Ci-Cô alkyl), or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (III), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl, -CO2(Ci-Cô alkyl), or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (IV), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl, -CO2(Ci-Cô alkyl), or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (V), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl, -CChiCi-Cô alkyl), or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (VI), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl, -CO2(Ci-Cô alkyl), or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I).
[0106] In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (II), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (III), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl; and R1, m, R2, n, R3, and o are as described
for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (IV), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (V), wherein X is -CH2-; Y is -O5 or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Ce alkyl; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (VI), wherein X is -CH2-; Y is -O- or -N(H)-; Z is 6-membered heteroaryl optionally substituted by Ci-Cô alkyl; and R1, m, R2, n, R3, and o are as described for Formula (I).
[0107] In some embodiments, provided herein is compound of Formula (I) is a compound of Formula 10 (II), wherein X is -CH2-; Y is -O- or -N(H)-; Z is -CO2(Ci-C6 alkyl) or -(Ci-C6 alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (III), wherein X is -CH2-; Y is -O- or -N(H)-; Z is -CO2(Ci-Cô alkyl) or -(Ci-Ce alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (IV), wherein X is 15 -CH2-; Y is -O- or -N(H)-; Z is -CChiCi-Cô alkyl) or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (I) is a compound of Formula (V), wherein X is -CH2-; Y is -O- or -N(H)-; Z is -CChiCi-Cô alkyl) or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for Formula (I). In some embodiments, provided herein is compound of Formula (VI) is a compound of Formula (II), wherein X is -CH2-; Y is -O- or
-N(H)-; Z is -CChiCi-Cô alkyl) or -(Ci-Cô alkyl)-OH; and R1, m, R2, n, R3, and o are as described for
Formula (I).
[0108] In the descriptions herein, it is understood that every description, variation, embodiment, or aspect of a moiety may be combined with every description, variation, embodiment, or aspect of other moieties the same as if each and every combination of descriptions is specifically and individually listed. 25 For example, every description, variation, embodiment, or aspect provided herein with respect to L of
Formula (I) may be combined with every description, variation, embodiment, or aspect of Ring A, Ring B, Ring C, R1, R2, R3, m, n, o, R4, R5, R6, R7, X, Y, Z, Z1, Z2, and R8 the same as if each and every combination were specifically and individually listed. It is also understood that ail descriptions, variations, embodiments, or aspects of Formula (I), where applicable, apply equally to other formulae 30 detailed herein, and are equally described, the same as if each and every description, variation, embodiment, or aspect were separately and individually listed for ail formulae. For example, ail descriptions, variations, embodiments, or aspects of Formula (I), where applicable, apply equally to any of the formulae as detailed herein, such as Formulae (II)-(VI), and are equally described, the same as if
each and every description, variation, embodiment, or aspect were separately and individually listed for ali formulae.
[0109] In some embodiments, provided is a compound selected from the compounds in Table 1 or a pharmaceutically acceptable sait thereof. In some embodiments, provided is a compound selected from 5 the compounds in Table 2 or a pharmaceutically acceptable sait thereof. Although certain compounds described in the présent disclosure, including in Table 1 and Table 2, are presented as spécifie stereoisomers and/or in a non-stereochemical form, it is understood that any or ail stereochemical forms, including any enantiomeric or diastereomeric forms, and any tautomers or other forms of any of the compounds ofthe présent disclosure, including in Table 1 and Table 2, are herein described.
Table 1.
Example | Structure |
7 | O F |
9 | ,Z Z' ZI IL·—IL -y—\ Z p ryZ JO /•O X |
11 | N—γ O-—. N J F F F |
Example | Structure |
8 | z. Z' ZI IL·—(( IL z 2 Xy~- Jf ^\^z |
10 | v N O·—. f F F F |
12 | X Z O O u.—Z \ z y tyZ Cx° 2 |
Table 2.
23 | I κ> Z ΰ Z, J ο Tl—Χ~\-·Π xz. ,ζ Z | 24 | 2χτ V /7 2 \ \ /-m |
25 | X ο ο 0 C/ ΰ-ΧΛ-''1 Ze .21 Z | 26 | O Γν-λ ί <x N xx > i XX Y H |
27 | Xzx X X -<.z z z^ Z^ J ~xr (\ Z y // // » n—r y~-n •Π O Z | 28 | Xzx z^o 2^^ z NS // n—/ K-n τι O · X |
29 | h2n OX ! nU^nUCX 1 TT T | 30 | χ/ p / ζΛ^<ν °-< Lk ;n N—X Jk h s Xi η i F |
31 | z Z- zx TT O jT ['Z QyO Z^ O7 X | 32 | / --N, >—N /O L N~K °~\ 1 Vcî Ks^N <X N XX 'N 1 TT T h |
33 | Q G-, KF OH | 34 | ,z Z' zx U.-Z KlL z y rX ^OKZ |
35 | I ο ΰ Ο^ο ζ^ J Ο τι— π Ο X | 36 | / z zx ?^° 2p^ M 71-#~\—71 71 O I |
37 | rw F | 38 | /=N - θΆ N 1 F\ N._, F |
39 | z Z' ZI jKZ °^o £> o \ | 40 | ° J \ z^ 0Ά0 z^ > /J” o 71—^J-TI IZ% ,Z Z |
41 | z J ZL 0 71—K X— 71 | 42 | r- >W«’ F |
43 | N-N O F x=/ hn-\ j VtY·’ | 44 | ZM° F |
45 | N A w 7 hn^ F <3 N χΎ> 'LJ Y H | 46 | \ .0 /N^C '°~Λ J'S Γ- F |
207 | ζο /°Ύ ΗΝ-. Λ? Ν'Ν Η | 208 | Ό KNy^ So HN-S \ |
209 | \ Η \ zk xS 8 b | 210 | Q Z, J )=° IZ ?ωχ θ''b |
211 | Ο )=O IZ^O | 212 | X ω t / z \ ÿ O “y° o |
213 | X Z ° V> \ /~z θ (Λ—/ / \ Z '^V Xm X xz >=° o \ | 214 | H ïX/X-X ^°ΎΝ—v—S O |
215 | O ÎL——IL Z-zZI | 216 | ï N 1 | H // /~N H T F |
217 | T o X ω z q Zx ,zx Z | 218 | HO F C/yiT'Ë0» |
219 | X .' oj À o “-O V1 | 220 | F |
221 | z 1 JT 2<l w Y o Z— / | 222 | nx5l ^cv~ F |
223 | F X/ ^Άχι Τ’! hn-J~ sT0 F | 224 | F N? L 11 M s-v^° \OH N^VVÎ_/ 1 ' H I l >VN F 'S Γ |
225 | F \ OH N^-jîX N \|—f~~ *X1 n X^ H lï S F | 226 | X o o Ç\__ ζ^γ Z. ,ZI z |
227 | N'A F X v-C^0^ v—Z y_N ' N | 228 | CVmï /C (JiÏN |
229 | H jt m z-N /-< '/f \=n N X | 230 | |
231 | £^z X A / ? | 232 | F N'\ N Ί Û Jl }-- h t t T F |
233 | Z Π O Z-Z -π // Δ ~-~/Z ω T o \—z /F % Z J | 234 | F \/ k” Yji N XX-s0 h tY Tj s f |
235 | 1 yX LL—ά —LL Z. ZX 'Z | 236 | F NvSi p-/ n Jx N A >-/ \ H T U |
F
or a pharmaceutically acceptable sait thereof.
Methods of Synthesis
[0110] Compounds of Formula (I) or any variation thereof may be prepared according to the general reactions shown in Schemes IA, IB, II, and III.
Scheme IA.
[0111] Scheme IA shows an exemplary route for preparing compounds of Formula (I), wherein Rx can be a group useful for conversion to a desired Z-Y-X group (such as shown in the non-limiting examples, Schemes IB, II, and III) and the remaining variables are as described herein. In some embodiments, compound I-A can be derivatized to form compound I-B, which can subsequently be coupled (e.g. under Suzuki coupling conditions) with an appropriate dihalide, compound I-C (wherein X is Cl or Br), to form compound I-D. Compound I-F can be achieved from compound I-D with an appropriate boronic acid ester, compound I-E, and métal catalyst. Rx can subsequently be derivatized to form the desired Z-Y-X group according to methods known in the art. In some embodiments, ring A, B, and C can be connected
in any order (e.g., ring A and ring B, followed by ring C as shown in Scheme IA; or ring B and ring C, followed by ring A) according to similar methods as described herein.
Scheme IB.
[0112] Scheme IB shows a route for prepàring compounds of Formula (I) wherein Ring B is a heteroarylene group such as pyridinylene, Ar and Ar’ represent aryl groups, and R is a non-aryl group, such as an alkyl group. In some embodiments, estérification of the hydroxyl group of compound Γ-A is achieved under standard conditions, such as in the presence of ArCl to form compound Γ-B or in the presence of R-LG (e.g. R-Cl) to form compound Γ-D. Suzuki coupling with the appropriate boronic ester in the presence of an appropriate palladium catalyst achieves compound Γ-C from compound Γ-B or compound I’-Ε from compound I’-D.
Scheme Π.
[0113] Scheme II shows a route for preparing compounds of Formula (I) wherein Rings A and B are each a heteroarylene group such as thiazolylene, Ring C is a phenylene or heteroarylene group, Ar represents an aryl group, and m, R3, and R1 are as defined herein. In some embodiments, estérification of compound II-A in the presence of, for example, ArCI or ArOH, under standard conditions achieves compound II-B. Compound II-B may be combined with compound Π-C in the presence of an appropriate boronic ester (such as 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2dioxaborolane) and a palladium catalyst to provide compound II-D. Compound Π-E can be achieved according to methods such as those described in Example S6. Compound Π-B may also be combined with compound Π-E in the presence of an appropriate boronic ester (such as 4,4,5,5-tetramethyI-2-(4,4,5,510 tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane) and a palladium catalyst. Subséquent deprotection under standard conditions provides compound II-D.
Scheme III.
Ill-G
[0114] Scheme III shows a route for preparing compounds of Formula (I) wherein Rings A and B are 15 each a heteroarylene group such as thiazolylene, Ring C is a phenylene or heteroarylene group, Ar represents an aryl group, R is a Ci-6 alkyl, and m, R3, and R* are as defined herein. In some embodiments, coupling of compound III-A and compound ΠΙ-Β under standard conditions achieves compound II-B. Compound III-C may be combined with compound III-D in the presence of an appropriate boronic ester (such as 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane) and a palladium catalyst to provide compound III-E. Compound III-C may also be combined with compound II21204
E in the presence of an appropriate boronic ester (such as 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyll,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane) and a palladium catalyst. Subséquent deprotection under standard conditions provides compound III-G.
[0115] It is understood that the synthetic processes disclosed herein may be modified to arrive at various compounds of the présent disclosure by sélection of appropriate reagents and starting materials.
In some embodiments, the synthetic processes disclosed herein may be modified to arrive at compounds of Formula (I) having other substituents as those shown in the Schemes described herein by sélection of appropriate reagents and starting materials.
[0116] Ail compounds of Formula (I) or any variation thereof as described herein which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of the disclosure can be converted to their free base or acid form by standard techniques. Pharmaceutical Compositions and Formulations
[0117] In another aspect, provided herein are pharmaceutical compositions of any of the compounds detailed herein. Thus, the présent disclosure includes pharmaceutical compositions comprising a compound disclosed herein, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient. Pharmaceutical compositions according to the disclosure may take a form suitable for oral, buccal, parentéral, nasal, topical, or rectal administration, or a form suitable for administration by inhalation. Pharmaceutical compositions of the présent disclosure comprise a compound of Formula (I), or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
[0118] A compound described herein can be used in the préparation of a composition, such as a pharmaceutical composition, by combining the compound as an active ingrédient with a pharmaceutically acceptable excipient. Some examples of materials which can serve as pharmaceutically acceptable excipients include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its dérivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; surfactants, such as polysorbate 80 (i.e., Tween 80); powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnésium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonie saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations. Pharmaceutical formulations may be prepared by known pharmaceutical methods. Suitable formulations can be found in, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), which is incorporated herein by reference.
[0119] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnésium stéarate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be présent in the compositions.
[0120] Examples of pharmaceutically-acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and métal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
[0121] Formulations of the présent disclosure include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parentéral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingrédient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingrédient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of active ingrédient, or from about 5% to about 70%, or about 10% to about 30%.
[0122] In certain embodiments, a formulation of the présent disclosure comprises an excipient selected from the group consisting of cyclodextrins, liposomes, micelle forming agents, e.g., bile acids and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the présent disclosure. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the présent disclosure.
[0123] Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules or as a solution or a suspension in an aqueous or non-aqueous liquid or as an oil-inwater or water-in-oil liquid émulsion or as an élixir or syrup or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the présent disclosure as an active ingrédient. A compound of the présent disclosure may also be administered as a bolus, electuary or paste.
[0124] In solid dosage forms of the disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingrédient is mixed with one or more pharmaceutically21204
acceptable carriers, such as sodium citrate or dicalcium phosphate and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quatemary ammonium compounds; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate and non-ionic surfactants; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stéarate, magnésium stéarate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, 10 the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0125] A tablet may be made by compression or molding, optionally with one or more accessory ingrédients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made in a suitable machine in which a mixture of the powdered compound is moistened with an inert liquid diluent.
[0126] The tablets and other solid dosage forms of the pharmaceutical compositions of the présent 20 disclosure, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceuticalformulating art. They may also be formulated so as to provide slow or controlled release of the active ingrédient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of stérile solid compositions that can be dissolved in stérile water or some other stérile injectable medium immediately before use. These compositions may also optionally contain opacifÿing agents and may be of a composition that they release the active ingredient(s) only or, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingrédient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
[0127] Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable émulsions, microemulsions, solutions, suspensions, syrups and élixirs. In
addition to the active ingrédient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
[0128] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0129] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth and mixtures thereof.
[0130] Formulations of the pharmaceutical compositions of the disclosure for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate and which is solid at room température, but liquid at body température and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[0131] Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under stérile conditions with a pharmaceutically-acceptable carrier and with any preservatives, buffers or propellants which may be required.
[0132] The ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose dérivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures thereof.
[0133] Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder or mixtures of these substances. Sprays can additionally contain customaiy propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0134] Pharmaceutical compositions of this disclosure suitable for parentéral administration comprise one or more compounds of the disclosure in combination with one or more pharmaceutically-acceptable stérile isotonie aqueous or nonaqueous solutions, dispersions, suspensions or émulsions or stérile powders which may be reconstituted into stérile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutés which render the formulation isotonie with the blood of the intended récipient or suspending or thickening agents.
[0135] Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the disclosure include water, éthanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like) and suitable mixtures thereof, vegetable oils, such as olive oil and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
[0136] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prévention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenyl sorbic acid and the like. It may also be désirable to include isotonie agents, such as sugars, sodium chloride and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[0137] In some cases, in order to prolong the effect of a drug, it is désirable to slow the absorption of the drug from subeutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of ciystalline or amorphous material having poor water solubility. The rate of absorption of the drug then dépends upon its rate of dissolution, which in tum, may dépend upon crystal size and crystalline form. Altematively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0138] Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodégradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodégradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue.
Methods of Use/Treatments
[0139] Compounds and compositions detailed herein, such as a pharmaceutical composition containing a compound of any formula provided herein, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier or excipient, may be used in methods of administration and treatment as provided herein. The compounds and compositions may also be used in in vitro methods, such as in vitro methods of administering a compound or composition to cells for screening purposes and/or for conducting quality control assays.
[0140] In one aspect, provided herein is a method of modulating bis-phosphoglycerate mutase (BPGM) comprising contacting either an effective amount of a compound described herein, or a pharmaceutically acceptable sait thereof, or an effective amount of a pharmaceutical composition provided herein, with the BPGM. In certain embodiments, the compounds of the présent disclosure are 5 allosteric modulators of BPGM that affect both the synthase and phosphatase functions of the enzyme.
[0141] In another aspect, provided herein is a method of treating sickle cell disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound described here, or a pharmaceutically acceptable sait thereof, or a therapeutically effective amount of a pharmaceutical composition described herein. In some embodiments, the sickle cell disease is HbSS, also 10 referred to as sickle cell anémia. In some embodiments, the sickle cell disease is HbSC. In some embodiments, the sickle cell disease is HbS beta thalassemia. In some embodiments, the sickle cell disease is HbSD, HbSE, or HbSO.
[0142] In some embodiments, the subject is a mammal. In some embodiments, the subject is a primate, dog, cat, rabbit, or rodent. In some embodiments, the subject is a primate. In some embodiments, the subject is a human. In some embodiments, the human is at least about or is about any of 18, 21,30, 50, 60, 65, 70, 80, or 85 years old. In some embodiments, the human is a child. In some embodiments, the human is less than about or about any of 21, 18, 15, 10, 5,4, 3,2, or 1 years old.
Dosing and Method ofAdministration
[0143] The phrases “parentéral administration” and “administered parenterally” as used herein mean 20 modes of administration other than enterai and topical administration, usually by injection and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
[0144] The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous System, such that it enters the patient’s System and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
[0145] These compounds may be administered to humans and other animais for therapy by any 30 suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
[0146] Regardless of the route of administration selected, the compounds of the présent disclosure, or the pharmaceutical compositions of the présent disclosure, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
[0147] Actual dosage levels of the active ingrédients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingrédient that is effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration, without being toxic to the patient.
[0148] The selected dosage level will dépend upon a variety of factors including the activity of the particular compound of the présent disclosure employed or the ester, sait or amide thereof, the route of administration, the time of administration, the rate of excrétion or metabolism of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the âge, sex, weight, condition, general health and prior medical history of the patient being treated and like factors well known in the medical arts. A daily, weekly or monthly dosage (or other time interval) can be used.
[0149] A physician or veterinarian having ordinaiy skill in the art can readily détermine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and then gradually increasing the dosage until the desired effect is achieved.
[0150] In general, a suitable daily dose of a compound of the disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect (e.g., inhibit necrosis). Such an effective dose will generally dépend upon the factors described above. Generally doses of the compounds of this disclosure for a patient, when used for the indicated effects, will range from about 0.0001 to about 100 mg per kg of body weight per day. In some embodiments, the daily dosage will range from 0.001 to
50 mg of compound per kg of body weight, and in some embodiments, from 0.01 to 10 mg of compound per kg of body weight.
[0151] If desired, the effective daily dose of the active compound may be administered as two, three, four, fïve, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
[0152] In certain embodiments, the présent disclosure relates to compounds for modulating BPGM, wherein the compounds are represented by Formula (I). In certain embodiments, the compounds of the présent disclosure are allosteric modulators of BPGM that affect both the synthase and phosphatase functions of the enzyme. In any event, the compounds of the présent disclosure, in some
embodiments,exert their effect on modulating BPGM at a concentration less than about 50 micromolar, or at a concentration less than about 10 micromolar or at a concentration less than 1 micromolar.
[0153] When the compounds of the présent disclosure are administered as pharmaceuticals, to humans and animais, they can be given per se or as a pharmaceutical composition containing, for example, 0.1% 5 to 99.5% (or, 0.5% to 90%) of active ingrédient in combination with a pharmaceutically acceptable carrier.
[0154] The compounds of the présent application or the compositions thereof may be administered once, twice, three or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment 10 would continue for at least 7 days, 14 days or 28 days, for one cycle of treatment. Treatment cycles are well known and are frequently altemated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in certain embodiments, may also be continuous.
[0155] When administered orally, the total daily dosage for a human subject may be between 1 mg and 15 1,000 mg, between about 1,000-2,000 mg/day, between about 10-500 mg/day, between about 50-300 mg/day, between about 75-200 mg/day or between about 100-150 mg/day.
[0156] The daily dosage may also be described as a total amount of a compound described herein administered per dose or per day. Daily dosage of a compound may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg/day, between about 1 to 2,000 mg/day, between about 1 to 1,000 20 mg/day, between about 10 to 500 mg/day, between about 20 to 500 mg/day, between about 50 to 300 mg/day, between about 75 to 200 mg/day or between about 15 to 150 mg/day.
[0157] In certain embodiments, the method comprises administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by incréments until clinical efficacy is achieved. Incréments of about 5, 10, 25, 50 or 100 mg can be used to increase the dose. The 25 dosage can be increased daily, every other day, twice per week or once per week.
[0158] In certain embodiments, a compound or pharmaceutical préparation is administered orally. In certain embodiments, the compound or pharmaceutical préparation is administered intravenously. Alternative routes of administration include sublingual, intramuscular and transdermal administrations. [0159] The préparations of the présent disclosure may be given orally, parenterally, topically or 30 rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. In certain embodiments, the administration is oral.
Kits/Artîcles of Manufacture
[0160] Also provided herein are kits that include a compound of the disclosure, or a pharmaceutically acceptable sait thereof, and suitable packaging. In certain embodiments, a kit further includes instructions for use. In one aspect, a kit includes a compound of the disclosure, or a pharmaceutically acceptable sait 5 thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.
[0161] Provided herein are also articles of manufacture that include a compound described herein, or a pharmaceutically acceptable sait thereof, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe and intravenous bag.
[0162] The kit can also contain instructions for using the compounds according to the disclosure. The kit can be compartmentalized to receive the containers in close confinement. As used herein, a kit such as a compartmentalized kit includes any kit in which compounds or agents are contained in separate containers. Illustrative examples of such containers include, but are not limited to, small glass containers, plastic containers or strips of plastic or paper. In some embodiments, the types of containers allow the skilled worker to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers include, but are not limited to, a container that will accept a compound or combination of compounds and/or other agents of the disclosure. One or more compounds or agents can be provided as a powder (e.g. lyophilized powder) or precipitate. Such compound(s) can be resuspended prior to administration in a solution that may be provided as part of the kit or separately available. A kit can contain compounds or agents in other forms such as liquids, gels, solids, as described herein. Different compounds and/or agents may be provided in different forms in a single kit.
EXAMPLES
[0163] The examples and préparations provided below further illustrate and exemplify the compounds of the présent disclosure and methods for testing such compounds. It is to be understood that the scope of the présent disclosure is not limited in any way by the scope of the following examples.
[0164] The Chemical reactions in the Examples described can be readily adapted to préparé a number of other compounds disclosed herein, and alternative methods for preparing the compounds of this disclosure are deemed to be within the scope of this disclosure. For example, the synthesis of nonexemplified compounds according to the présent disclosure can be performed by modifications apparent to those skilled in the art, for example by appropriately protecting interfering groups, by utilizing other suitable reagents known in the art other than those described, or by making routine modification of reaction conditions, reagents, and starting materials. Altematively, other reactions disclosed herein or known in the art will be recognized as having applicability for preparing other compounds of the présent disclosure.
[0165] The following abbreviations may be relevant for the application.
Abbreviations
ACN: acetonitrile
Bu: butyl
DCM: dichloromethane
DEAD: diethyl azodicarboxylate
DIAD: diisopropyl azodicarboxylate
DIEA: N,N-diisopropylethylamine
DMF: N,N-dimethylformamide
DMSO: dimethylsulfoxide
ES-MS: electrospray ionization mass spectrometry
EtOAc or EA: ethylacetate
EtOH: éthanol
HPLC: high performance liquid chromatography
LCMS: liquid chromatography-mass spectrometry
Me: methyl
MeOH: methanol
NBS: N-bromosuccinimide
NMR: nuclear magnetic résonance
OAc: acetate
Pd(dppf)C12.CH2C12: [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
PE: petroleum ether
PPhj: triphenylphosphine sat.·. saturated
SEM-C1: 2-(trimethylsilyl)ethoxymethyl chloride
TB AF: tetra-n-butylammonium fluoride
TBSC1: tert-butyldimethylsilyl chloride
TFA: trifluoroacetic acid
THF: tetrahydrofuran
TLC: thin layer chromatography
Synthetic Examples
[0166] Example SI. Préparation of 4-fluoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]triazole (1) (Key Intermediate A).
F
(1)
1.SEMCI, Base
Key Intermediate A (1)
[0167] Step 1: Synthesis of 6-bromo-4-fluoro-l-((2-(trimethyIsilyI)ethoxy)methyl)-lHbenzo[d][1^3]triazole (la).
F
SEM (1a)
To a solution of 5-bromo-7-fluoro-lH-benzotriazole (3 g, 12.50 mmol, 1 eq) in THF (100 mL) was added NaH (749.93 mg, 18.75 mmol, 60% purity, 1.5 eq). The mixture was stirred at 0 °C for 15 min. Then to the mixture was added SEM-C1 (3.13 g, 18.75 mmol, 3.32 mL, 1.5 eq). The mixture was stirred at 25 °C for 45 min. Water (40 mL) was added to the mixture. The mixture was extracted with ethyl acetate (40 mL x 2). The combined organic phase was washed with brine (40 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuuo. The residue was purified with flash silica gel chromatography (ISCO®; 20 SepaFlash® Silica Flash Column, Eluent of 0-10% Petroleum/Ethyl acetate ether gradient @ 30 mL/min) to give 2-[(6-bromo-4-fluoro-benzotriazol-l-yI)methoxy]ethyl-trimethyl-silane la (1.4 g, 3.64 mmol, 58.2% yield, 90% purity) as a solid. *H NMR (400 MHz, CDCI3) δ ppm 7.70 (d, J= 1.2 Hz, 1H), 7.25 (dd, J= 9.2, 1.2 Hz, 1H), 5.96 (s, 2H), 3.56-3.61 (m, 2H), 0.89-0.95 (m, 2H), -0.04 (s, 9H).
[0168] Step 2: Synthesis of 4-fluoro-6-(4,4,5,5-tetramethyl-l^,2-dioxaborolan-2-yl)-l-((2(trimethylsilyI)ethoxy)methyl)-lH-benzo[d][1^3]triazole (1). A mixture of 2-[(6-bromo-4-fluorobenzotriazol-l-yl)methoxy]ethyl-trimethyl-silane la (600.00 mg, 1.56 mmol, 1 eq), potassium acetate (382.63 mg, 3.90 mmol, 2.5 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)5 1,3,2-dioxaborolane (514.82 mg, 2.03 mmol, 1.3 eq) and cyclopentyl(diphenyl)phosphane;dichloromethane;dichloropalladium; iron (127.35 mg, 155.95 pmol, 0.1 eq) in dioxane (8 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 12 h under N2 atmosphère. Water (20 mL) was added to the mixture. The mixture was extracted with ethyl acetate (40 mL x 2). The combined organic phase was washed with brine (40 mL), dried over anhydrous Na2SÛ4, fïltered and concentrated in vacuo. The residue was purified with flash silica gel chromatography (ISCO®; 20g SepaFlash® Silica Flash Column, Eluent of 0~30% Petroleum/Ethyl acetate ether gradient @ 30 mL/min) to give 2-[[4-fluoro-6-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)benzotriazol-l-ÿl]methoxy]ethyl-trimethyl-silane 1 (800 mg, 1.42 mmol, 91.3% yield, 70% purity) as a solid. ’HNMR (400 MHz, CDClj) δ ppm 7.96 (s, 1H), 7.46 (d, J= 10.2 Hz, 1Η), 6.01 (s,
2H), 3.58-3.64 (m, 2H), 1.39 (s, 12H), 0.89-0.95 (m, 2H), -0.05 (s, 9H).
[0169] Example S2. Préparation of 4,7-difIuoro-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yI)1/Z-benzotriazole (2) (Key Intermediate B).
F 1 H JL X 'N Bpin^^'y' N F (2) Scheme 2. F F /kxNO2 NH4CI/Fe χΑγ-ΝΗ2 Br'xyiik'NH2 Bfyillt F F 2a 2b Λ Pd Cat. F | F 1 H NaNO2/AcOH /An ------------* J JL n BryN F 2c |
Key Intermediate B (2)
[0170] Step 1: Synthesis of 3-bromo-2,5-difluoro-6-nitro-aniline (2a).
(2a)
To a solution of l-bromo-2,5-difluoro-4-nitro-benzene (5 g, 21.01 mmol, 1 eq) in DMSO (100 mL) was added amino(trimethyl)ammonium iodide (5.09 g, 25.21 mmol, 1.2 eq), then Z-BuOK (9.43 g, 84.04 mmol, 4 eq) was added in one portion at 15 °C. After addition, the mixture was stirred at 15 °C for 15 min. TLC (PE/EtOAc =10/1) showed the reaction was completed. The reaction mixture was quenched with 10% HCl (30 mL) to make pH = 4-5 at 10 °C, then the mixture was poured into water (400 mL) and extracted with EtOAc (300 mL x 3). The combined organic layers were washed with water (300 mL x 3), brine (300 mL x 3) and dried over Na2SC>4, fïltered and concentrated under reduced pressure. The residue' was purified with flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~3.4% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 3-bromo-2,5-difluoro-6-nitroaniline 2a (1.8 g, 6.40 mmol, 15.2% yield, 90% purity) as a solid. ’H NMR (400 MHz, DMSO-dô) <5 ppm 7.21 (s, 2H), 7.00 (dd, J= 5.6, 11.2 Hz, 1H).
[0171] Step 2: Synthesis of 4-bromo-3,6-difluoro-benzene-l,2-diamine (2b).
F /L/NH2 Br-^^Y^NHz F (2b)
To a solution of 3-bromo-2,5-difluoro-6-nitro-aniline 2a (2.6 g, 9.25 mmol, 1 eq) in EtOH (25 mL), THF (25 mL) and H2O (15 mL) was added NH4CI (4.95 g, 92.49 mmol, 10 eq) and Fe power (5.17 g, 92.49 mmol, 10 eq). The reaction mixture was stirred at 55 °C for 2 h. TLC (PE/EtOAc = 10/1) showed the reaction was completed. The reaction mixture was fïltered, filtrate was dried over Na2SC>4, fïltered and concentrated to give crude 4-bromo-3,6-difluoro-benzene-l,2-diamine 2b (2 g, 8.07 mmol, 87.3% yield, 90% purity) as a solid. Ή NMR (400 MHz, DMSO-rZ6) δ ppm 6.64 (dd, J= 6.0, 10.0 Hz, 1H), 5.05 (br.s, 2H), 4.89 (br.s, 2H).
[0172] Step 3: Synthesis of 6-bromo-4,7-difluoro-lH-benzotriazole (2c)
(2c)
To a solution of 4-bromo-3,6-difluoro-benzene-l,2-diamine 2b (2 g, 8.97 mmol, 1 eq) in HOAc (15 mL) and H2O (15 mL) was added HCl (12 M, 1.12 mL, 1.5 eq) and a solution ofNaNCh (1.55 g, 22.42 mmol, 2.5 eq) in H2O (15 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 30 min. TLC (PE/EtOAc = 1/1) showed the reaction was completed. The reaction mixture was poured into water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with sat. NaHCCh (30 mL x 3) and dried over Na2SC>4, filtered and concentrated under reduced pressure. The residue was purifïed with flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~10% Ethyl acetate/Petroleum ether gradient @ 40 mL/min) to give 6-bromo-4,7-difluoro-177-benzotriazole 2c (1.6 g, 6.15 mmol, 68.6% yield, 90% purity) as a solid. Ή NMR (400 MHz, CDCI3) δ ppm 7.28 (dd, J= 4.4, 8.4 Hz, 1H).
[0173] Step 4: Synthesis of 4,7-difluoro-6-(4,4,5,5-tetramethyI-l,3,2-dioxaborolan-2-yI)-l.f7benzotriazole (2). A mixture of 6-bromo-4,7-difluoro-177-benzotriazole 2c (1.5 g, 5.77 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (8.79 g, 34.62 mmol, 6 eq), Pd(dppf)C12.CH2C12 (471.14 mg, 576.92 umol, 0.1 eq) and KOAc (4.53 g, 46.15 mmol, 8 eq) in DMSO (70 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100 °C for 12 h. The reaction mixture was poured into water (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with water (100 mL x 3), brine (80 mL x 3) and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purifïed with flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~28% Ethyl acetate/Petroleum ether gradient @ 40 mL/min) to give 4,7-difluoro-6-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-lH-benzotriazole 2 (1.4 g, 3.74 mmol, 64.8% yield, 75% purity) as an oil. 'H NMR (400 MHz, CDCl3)<5ppm 7.37 (d, J = 9.6 Hz, 1H), 1.38 (s, 12H).
[0174] Example S3. Préparation of (5-bromo-4-methyl-thiazol-2-yl)methanamine (3) (Key Intermediate C).
nh2nh2
Key Intermediate C (3)
[0175] Step 1: Synthesis of cyanomethyl benzoate (3a).
(3a)
To a suspension of benzoic acid (500 g, 4.09 mol, 625.00 mL, 1 eq) in DMF (1500 mL), K2CO3 (700.00 . g, 5.06 mol, 1.24 eq) was added and the mixture was stirred until the évolution of gas has ceased. The reaction mixture was cooled to 0°C and a solution of 2-bromoacetonitrile (491.10 g, 4.09 mol, 272.83 mL, 1 eq) in DMF (500 mL) was added drop-wise. The reaction mixture was stirred ovemight (12 hr) at room température (25°C). TLC (Petroleum ether/Ethyl acetate=3/l) indicated the material was consumed completely and one new spot formed. The reaction mixture was filtered and diluted with H2O (3000 mL) and extracted with EA (2000 mL x 2). The combined organic layers were washed with brine (2000 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure, the residue was purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate=10/l to 5/1) to give cyanomethyl benzoate 3a (650 g, 4.03 mol, 98.51% yield) as an oil. ’HNMR (400 MHz, CHLOROFORM-d) δ = 8.11 - 8.03 (m,
2H), 7.67 - 7.60 (m, 1 H), 7.53 - 7.45 (m, 2H), 4.97 (s, 2H).
[0176] Step 2: Synthesis of (2-amino-2-thioxo-ethyl) benzoate (3b).
(3b)
Cyanomethyl benzoate 3a (170 g, 1.05 mol, 1 eq) and thioacetamide (118.88 g, 1.58 mol, 1.5 eq) were dissolved in DMF (800 mL). HCl/dioxane (4 M, 1.02 L, 3.87 eq) was added and the mixture was heated at 100°C for 2 h. TLC (Petroleum ether/Ethyl acetate=l/l) indicated the material remained, and one major new spot with larger polarity was detected. The reaction mixture was reduced pressure to give a residue and then diluted with H2O (1.2 L) and extracted with ethyl acetate (1.2 L x 2). The combined organic layers were washed with brine (1.2 L x 2), dried over Na2SO4, filtered and concentrated under reduced pressure and the crude product was triturated with Petroleum ether/Ethyl acetate=3/l (300 mL) at 25°C for 30 min to give (2-amino-2-thioxo-ethyl) benzoate 3b (130 g, crude) as a solid. ’HNMR (400 MHz, DMSO-de) δ = 9.95 (br s, 1H), 9.37 (br s, 1H), 8.13 - 8.04 (m, 2H), 7.72 - 7.64 (m, 1H), 7.60 - 7.49 (m, 2H), 4.97 (s, 2H).
[0177] Step 3: Synthesis of (4-methyIthiazol-2-yl)methyl benzoate (3c).
O
(3c)
To a solution of (2-amino-2-thioxo-ethyl) benzoate 3b (900 g, 4.61 mol, 1 eq) in EtOH (9000 mL) was added l-chloropropan-2-one (639.77 g, 6.91 mol, 1.5 eq). The mixture was stirred at 90°C for 12 hr. LCMS showed the material was consumed completely and one main peak with desired mass was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The reaction mixture was diluted with H2O (1000 mL) and extracted with Ethyl acetate (1000 mL x 2). The combined organic layers were washed with brine (1000 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure to give (4-methylthiazol-2-yl)methyl benzoate 3c (1000 g, crude) as an oil. 'HNMR (400 MHz, DMSO-dô) δ = 8.03 - 7.97 (m, 2H), 7.72 - 7.66 (m, 1H), 7.59 - 7.53 (m, 2H), 7.34 (d, J= 1.0 Hz, 1H), 5.58 (s, 2H), 2.37 (d, J= 0.9 Hz, 3 H).
[0178] Step 4: Synthesis of (4-methylthiazol-2-yl)methanol (3d).
HO (3d)
To a solution of (4-methylthiazol-2-yl)methyl benzoate 3c (250 g, 1.07 mol, 1 eq) in MeOH (1000 mL) was added NaOH (2 M, 1.25 L, 2.33 eq). The mixture was stirred at 25°C for 2 hr. TLC (Petroleum ether/Ethyl acetate=O/l) indicated the material was consumed completely and one new spot formed. The reaction mixture was diluted with H2O (300 mL) and extracted with EA (300 mL x 2). The combined organic layers were washed with brine (300 mL x 2), dried over Na2SC>4, filtered and concentrated under reduced pressure to give (4-methylthiazol-2-yl)methanol 3d (340 g, crude) as an oil. 'H NMR (400 MHz, DMSO-de) δ = 7.13 (d, J= 0.7 Hz, 1H), 5.96 (t, J= 5.9 Hz, 1H), 4.67 (d, J= 5.9 Hz, 2H), 2.32 (s, 3H). [0179] Step 5: Synthesis of (5-bromo-4-methyl-thiazol-2-yl)methanol (3e).
(3e)
To a solution of (4-methylthiazol-2-yl)methanol 3d (100 g, 774.11 mmol, 1 eq) in MeCN (1000 mL) was added NBS (165.34 g, 928.94 mmol, 1.2 eq) at 0°C. The mixture was stirred at 25°C for 0.5 h. LCMS showed the material was consumed completely and one main peak with desired mass was detected. The reaction mixture was diluted with H2O (500 mL) and extracted with EA (500 mL x 2). The combined organic layers were washed with brine (500 mL x 2), dried over Na2SÜ4, filtered and concentrated under reduced pressure to give a residue and purified by column chromatography (S1O2, Petroleum ether/Ethyl acetate=10/l to 5/1) to give (5-bromo-4-methyl-thiazol-2-yl)methanol 3e (106 g, 509.43 mmol, 65.81% yield) as a solid. Ή NMR (400 MHz, CHLOROFORM-d) δ = 4.83 (s, 2H), 3.40 - 3.12 (m, 1H), 2.36 (s, 3 H).
[0180] Step 6: Synthesis of 2-[(5-bromo-4-methyl-thiazol-2-yl)methyl]isoindoline-l,3-dione (3f). O
(3f)
To a solution of (5-bromo-4-methyl-thiazol-2-yl)methanol 3e (3 g, 14.42 mmol, 1 eq), isoindolme-1,3dione (2.76 g, 18.74 mmol, 1.3 eq) and triphenylphosphine (4.92 g, 18.74 mmol, 1.3 eq) in THF (40 mL). The mixture was stirred at 0°C for 0.5h. Then DIAD (3.79 g, 18.74 mmol, 3.64 mL, 1.3 eq) was added. The mixture was stirred at 25°C for 1.5 h. After completion, the réaction mixture was poured into ammonium chloride saturated aqueous solution (50 mL) and extracted with ethyl acetate (20 mL x 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~35% Ethyl acetate/Petroleum ether gradient @ 20 mL/min). The eut fraction was concentrated under reduced pressure to give 2-[(5-bromo-4-methyl-thiazol-2yl)methyl]isoindoline-l,3-dione 3f (7.5 g, 10.45 mmol, 72.51% yield, 47% purity) as a solid.
[0181] Step 7: Synthesis of (5-bromo-4-methyl-thiazol-2-yl)methanamine (3). To a solution of 2[(5-bromo-4-methyl-thiazol-2-yl)methyl]isoindoline-l,3-dione 3f (7.5 g, 10.45 mmol, 47% purity, 1 eq) in MeOH (150 mL) was added NH2NH2.H2O (7.85 g, 156.81 mmol, 7.62 mL, 15 eq). The mixture was stirred at 25°C for 16 h. After completion, the reaction mixture was filtered and concentrated under reduced pressure to give a residue. The reaction mixture was poured into IN HCl (30 mL) to pH=3. Next, EA (100 mL) was added to the mixture. Then aqueous phase was added to the 2NNaOH (50 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give (5-bromo-4-methyl-thiazol-2yl)methanamine 3 (2.5 g, crude) as a solid. 'H NMR (400MHz, DMSO-de) δ = 3.90 (s, 2H), 2.33 (s, 2H), 2.26 (s, 3H).
[0182] Example S4. Préparation of 4-(4-bromothiazol-2-yl)-2,3,6-trifluoro-phenol (4) (Key Intermediate D).
(4)
Scheme 4.
OH
NBS
4a
Pd Cat.
BrX^N
Pd Cat.
OH
Key Intermediate D (4)
F
A B d
OH
4b
[0183] Step 1: Synthesis of 4-bromo-2,3,6-trîfluoro-phenol (4a).
(4a)
A mixture of2,3,6-trifluorophenol (20 g, 135.06 mmol, 1 eq), NBS (27.64 g, 155.32 mmol, 1.15 eq) in CHCh (500 mL) was stirred at 0 °C for 2 h under Nz atmosphère. The reaction mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~15% Ethyl acetate/Petroleum ether gradient @ 80mL/min) to give 4-bromo-2,3,6-trifluoro-phenol 4a (30 g, 118.95 mmol, 88.1% yield, 90% purity) as a solid. Ή NMR (400 MHz, DMSO-cfc) <5 ppm 11.16 (s, 1H), 7.67-7.42 (m, 1H).
[0184] Step 2: Synthesis of 2,3,6-trifluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yl)phenol (4b).
(4b)
A mixture of 4-bromo-2,3,6-trifluoro-phenol 4a (10 g, 39.65 mmol, 1 eq), Pd(dppf)Ch (1.45 g, 1.98 mmol, 0.05 eq), KOAc (9.73 g, 99.13 mmol, 2.5 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,215 dioxaborolan-2-yl)-l,3,2-dioxaborolane (20.14 g, 79.30 mmol, 2 eq) in dioxane (250 mL) was degassed and purged with Nz for 3 times, then the mixture was stirred at 80 °C for 12 h. The mixture was concentrated and then water (200 mL) was added then extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over NazSCh, filtered and concentrated. The residue was purified with flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~20% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 2,3,6-trifluoro-4(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol 4b (4 g, 13.14 mmol, 33.1% yield, 90% purity) as a solid. ’H NMR (400 MHz, DMSO-î/6) δ ppm 11.23 (s, 1H), 7.05-6.96 (m, 1H), 1.24 (s, 12H).
[0185] Step 3: Synthesis of 4-(4-bromothiazol-2-yl)-2,3,6-trifluoro-phenol (4). A mixture of 2,3,6trifluoro-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol 4b (0.5 g, 1.64 mmol, 1 eq), Pd(dppf)C12 (120.15 mg, 164.21 pmol, 0.1 eq), K3PO4.3H2O (1.31 g, 4.93 mmol, 3 eq), 2,4-dibromothiazole (1.20 g, 4.93 mmol, 3 eq) in dioxane (8 mL) and H2O (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 60 °C fqr 0.5 h under microwave (2 Bar). TLC (PE/EtOAc = 5/1) ind.icated the reaction was completed. The mixture was concentrated and water (200 mL) was added. The mixture was extracted with EtOAc (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated. The residue was purified with flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 4-(4-bromothiazol-2-yl)-2,3,6-trifluoro-phenol 4 (0.28 g, 812.67 pmol, 49.5% yield, 90% purity) as a solid. *H NMR (400 MHz, DMSO-îZô) δ ppm 11.72 (br s, 1H), 8.05 (s, 1H), 7.74-7.71 (m, 1H).
[0186] Example S5. Préparation of 5-(6-chloro-2-pyridyI)-4-methyl-2-(pyrimidin-2yloxymethyl)thiazole (5) (Key Intermediate E).
N—Y
(5)
5b
Key Intermediate E (5)
[0187] Step 1: Synthesis of 5-bromo-2-(((tert-butyldimethyIsilyl)oxy)methyI)-4-methylthiazole (5a).
TBSO
(5a)
To a solution of (5-bromo-4-methyl-thiazol-2-yl)methanol 3e (40 g, 173.01 mmol, 1 eq) in anhydrous DCM (150 mL) was added TBSC1 (33.90 g, 224.92 mmol, 27.56 mL, 1.3 eq) and imidazole (17.67 g, 259.52 mmol, 1.5 eq) at 0 °C. The mixture was warmed to 25 °C and stirred for 12 h. The reaction mixture was concentrated under reduced pressure to remove DCM. The residue was diluted with H2O (100 mL) and extracted with EtOAc (150 mL x 3). The combined organic layers were washed with bnne (100 mL x 3), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~3% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give (5-bromo-4methyl-thiazol-2-yl)methoxy-tert-butyl-dimethyl-silane 5a (57 g, 159.15 mmol, 92.0% yield, 90% purity) as an oil. Ή NMR (400MHz, CDC13) δ ppm 4.85 (s, 2H), 2.36 (s, 3H), 0.95 (s, 9H), 0.13 (s, 6H).
[0188] Step 2: Synthesis of 2-(((tert-butyldimethylsilyl)oxy)methyI)-4-methyl-5-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yI)thiazole (5b).
TBSO
Bpin (5b)
To a solution of (5-bromo-4-methyl-thiazol-2-yl)methoxy-Zer/-butyl-dimethyl-silane 5a (10 g, 27.92 mmol, 1 eq) in anhydrous THF (200 mL) was added n-BuLi (2.5 M, 16.75 mL, 1.5 eq) dropwise at -78 °C under N2. The reaction mixture was stirred at -78 °C for 0.5 h. 4,4,5,5-tetramethyl-l,3,2-dioxaborolane (8.93 g, 69.80 mmol, 10.13 mL, 2.5 eq) was added to the mixture in dropwise at -78 °C for 0.5 h. After addition, the reaction was warmed to 25 °C and stirred for another 12 h. The reaction was quenched with saturated NH4CI (100 mL) at 0 °C and extracted with EtOAc (200 mL x 3) and washed with brine (500 mL x 3). The combined organic layers were dried over anhydrous Na2SÛ4, filtered and concentrated to give crude residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0-10% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to give 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)thiazole 5b (6 g, 14.62 mmol, 52.4% yield, 90% purity) as an oil. 'H NMR (400MHz, CDCI3) <5 ppm 4.95 (s, 2H), 2.60 (s, 3H), 1.34 (s, 12H), 0.96 (s, 9H), 0.13 (s, 6H).
[0189] Step 3: Synthesis of 2-(((tert-butyldimethy!silyl)oxy)methyl)-5-(6-chloropyridin-2-yI)-4methylthiazole (5c).
TBSO
Cl (5c)
To a solution of 2,6-dichloropyridine (2.34 g, 15.84 mmol, 1.3 eq) in dioxane (120 mL), H2O (12 mL) was added 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan
2-yl)thiazole 5b (5 g, 12.18 mmol, 1 eq), Cs2CCh (11.91 g, 36.55 mmol, 3 eq) and Pd(dppf)Cl2 (534.81 mg, 730.91 pmol, 0.06 eq). The mixture was stirred at 90 °C for 2 h under N2 atmosphère. The reaction was diluted with water (100 mL) and extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purifîed by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0-10% Ethylacetate/Petroleum ethergradient @ 35mL/min) to give 2-(((tertbutyldimethylsilyl)oxy)methyl)-5-(6-chloropyridin-2-yl)-4-methylthiazole 5c (1.9 g, 4.82 mmol, 39.5% yield, 90% purity) as an oil. ’H NMR (400 MHz, CDCh) δ ppm 7.68 (t, J- 7.6 Hz, 1H), 7.44 (d, J= 7.6 Hz, 1H), 7.21 (d, J= 7.6 Hz, 1H), 4.94 (s, 2H), 2.67 (s, 3H), 0.97 (s, 9H), 0.16 (s, 6H).
[0190] Step 4: Synthesis of [5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methanol (5d). HO
Cl (5d)
To a solution of 2-(((tert-butyldimethylsilyl)oxy)methyl)-5-(6-chloropyridin-2-yl)-4-methylthiazole 5c (1.9 g, 4.82 mmol, 1 eq) in THF (15 mL) was added TBAF (1 M, 5.78 mL, 1.2 eq). The mixture was stirred at 25 °C for 1 h under N2 atmosphère. TLC (EtOAc) indicated the starting material was consumed. The reaction mixture was concentrated under reduced pressure to give residue. The residue was purifîed by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 100% Ethyl acetate gradient @ 30 mL/min) to give [5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methanol 5d (1 g, 3.74 mmol, 77.6% yield, 90% purity) as a solid. Ή NMR (400 MHz, CDCI3) δ ppm 7.70 (t, J= 7.6 Hz, 1H), 7.45 (d, J= 7.6 Hz, 1H), 7.23 (d, J= 8.0 Hz, 1H), 4.93 (d, J= 6.0 Hz, 2H), 2.69 (s, 3H).
[0191] Step 5: Synthesis of 5-(6-chloro-2-pyridyl)-4-methyl-2-(pyrimidin-2-yloxymethyl)thiazole (5). To a solution of [5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methanol 5d(l g, 3.74 mmol, 1 eq) in anhydrous DMF (10 mL) was added NaH (164.50 mg, 4.11 mmol, 60% purity, 1.1 eq). The mixture was stirred at 0 °C for 15 min. Then 2-chloropyrimidine (1.28 g, 11.22 mmol, 3 eq) was added to the mixture at 0 °C. After addition, the mixture was stirred at 25 °C for 45 min. TLC (Petroleum ether/EtOAc = 1:1) indicated one major new spot formed. Water (40 mL) was added and extracted with ethyl acetate (40mL x 2). The combined organic phase was washed with brine (40 mL), dried with anhydrous Na2SÛ4, filtered and concentrated under reduced pressure. The residue was purifîed by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-70% EtOAc/PE ethergradient @30 mL/min) to give 5-(6-chloro-2-pyridyl)-4-methyl-2-(pyrimidin-221204
yloxymethyl)thiazole 5 (700 mg, 1.98 mmol, 52.9% yield, 90% purity) as a solid. *H NMR (400 MHz, CDCh) δ ppm 8.58 (d, J= 4.8 Hz, 2H), 7.68 (t, J= 8.0 Hz, 1H), 7.44 (d, J= 7.6 Hz, 1H), 7.22 (d, J= 7.6 Hz, 1H), 7.02 (t, J= 4.8 Hz, 1H), 5.71 (s, 2H), 2.71 (s, 3H).
[0192] Example S6. Préparation of 2-[[5-(4-bromothiazol-2-yl)-4,7-difluoro-benzotriazol-25 yl]methoxy]ethyl-trimethyl-silane (6) (Key Intermedîate F).
F (6)
Scheme 6.
Key Intermedîate B (2)
Key Intermedîate F (6)
[0193] Step 1: Sÿnthesis of 4-bromo-2-(4,7-difluoro-lH-benzotriazoI-5-yl)thiazoIe (6a).
(6a)
A mixture of 4,7-difluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzotriazole Key Intermedîate B (2) (8 g, 28.46 mmol, 1 eq), 2,4-dibromothiazole (13.83 g, 56.93 mmol, 2 eq), Na2COa (9.05 g, 85.39 mmol, 3 eq) and Pd(dppf)C12.CH2C12 (2.32 g, 2.85 mmol, 0.1 eq) in dioxane (100 mL) and H2O (25 mL) was degassed and charged with N2 three times. The reaction mixture was stirred at 80°C for h under N2. LCMS showed 22% of desired was observed. Ice-water (300 mL) was added, acidifïed by IN HCl (-180 mL) to pH=5, extracted with EtOAc (500 mL x 2), washed with brine (300 mL), dried over anhydrous Na2SO4, filtered and concentrated to give the crude. Then purified by reversed-phase HPLC (0.1% FA condition) to give 4-bromo-2-(4,7-difluoro-lH-benzotriazol-5-yl)thiazole 6a (1.3 g, 4.10 mmol, 14.40% yield) as a solid. ’HNMR (400 MHz, DMSO-d6) δ = 8.13 (s, 1H), 7.95 - 7.90 (m, 1H).
[0194] Step 2: Synthesis of 2-[[5-(4-bromothiazol-2-yl)-4,7-difluoro-benzotriazol-2yl]methoxy]ethyl-trimethyl-silane (6). To a suspension of NaH (416.22 mg, 10.41 mmol, 60% purity, 3 eq) in THF (7 mL) was added a solution of 4-bromo-2-(4,7-difluoro-lH-benzotriazol-5-yl)thiazole 6a (1.1 g, 3.47 mmol, 1 eq) in THF (7 mL) at 0°C under N2 atmosphère. The mixture was stirred at 0°C for 30 min, then SEM-C1 (751.82 mg, 4.51 mmol, 798.11 uL, 1.3 eq) was added. The resulting mixture was stirred at 0 °C under N2 atmosphère for 30 min. TLC showed material was consumed and some new spots forméd. The reaction mixture was quenched with sat. NH4CI (20 mL) solution and extracted with ethyl acetate (20 mL x 2), the organic layer was dried over Na2SC>4, filtered, filtrate was concentrated under reduced pressure. The residue was purified with flash silica gel chromatography (Eluent of 0-10% Ethyl acetate/Petroleum ether) to give 2-[[5-(4-bromothiazol-2-yl)-4,7-difluoro-benzotriazol-2yl]methoxy]ethyl-trimethyl-silane 6 (550 mg, 1.23 mmol, 35.44% yield) as a solid. 'H NMR (400MHz, CHLOROFORM-d) δ = 8.06 (dd, J=4.6, 10.6 Hz, 1H), 7.44 (s, 1H), 6.03 (s, 2H), 3.84 - 3.77 (m, 2H), 1.03 - 0.97 (m, 2H), 0.00 (s, 9H).
[0195] Example S7. Préparation of 5-[2-(7-fluoro-l/7-benzotriazol-5-yl)thiazol-4-yl]-4-methyl-2(pyridazin-3-yloxymethyl)thiazo!e (7).
General Scheme for Compounds 7,10 and 11.
F
[0196] Step 1: Synthesis of 5-bromo-4-methyl-2-(pyridazin-3-yloxymethyl)thiazole (7a).
To a mixture of (5-bromo-4-methyl-thiazoI-2-yl)methanoI 3e (0.6 g, 2.60 mmol, 1 eq) in THF (15 mL) was added NaH (311.39 mg, 7.79 mmol, 60% purity, 3 eq) and purged with N2 for 3 times, and then the mixture was stirred at 20 °C for 0.5 h. 3-Chloropyridazine (356.68 mg, 3.11 mmol, 1.2 eq) was added to the reaction mixture, the mixture was stirred at 20 °C for 12 h. The reaction mixture was quenched with addition of water (50 mL) at 0 °C. The mixture was extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SC>4, filtered and concentrated. The residue 10 was purified with flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0-70% Ethylacetate/Petroleum ether gradient @ 40 mL/min) to give 5-bromo-4-methyl-2-(pyridazin3-yloxymethyl)thiazole 7a (110 mg, 345.97 pmol, 13.3% yield, 90% purity) as a solid. Ή NMR (400 MHz, DMSO-Jô) δ ppm 8.97 (d, J= 4.4 Hz, 1H), 7.71 (dd, J= 4.4, 9.0 Hz, 1H), 7.36 (dd, J= 1.4, 8.8 Hz, 1H), 5.74 (s, 2H), 2.34 (s, 3H).
[0197] Step 2: Synthesis of 2-[[5-(4-bromothiazoI-2-yI)-7-fluoro-benzotriazol-l-yI]methoxy]ethyltrimethyl-silane (7b).
N-k,
F (7b)
A mixture of 2-[[7-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzotriazol-1yl]methoxy]ethyl-trimethyl-silane Key Intermediate A (1) (0.6 g, 1.22 mmol, 1 eq), Pd(dppf)C12 (89.29 20 mg, 122.03 pmol, 0.1 eq), K3PO43H2O (974.96 mg, 3.66 mmol, 3 eq), 2,4-dibromothiazole (741.11 mg,
3.05 mmol, 2.5 eq) in dioxane (8 mL) and H2O (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 60 °C for 0.5 h under microwave (Ibar). The mixture was concentrated and then water (100 mL) was added. The mixture was extracted with EtOAc (80 mL x 3). The combined organic layers were washed with brine (80 mL), dried over Na2SO4, filtered and concentrated. The residue was purified with flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, Eluent of 0-30% Ethylacetate/Petroleum ether gradient @ 40 mL/min) to give 2-[[5-(4-bromothiazol-2-yl)-7fluoro-benzotriazol-l-yl]methoxy]ethyl-trimethyl-silane 7b (0.51 g, 1.07 mmol, 87.6% yield, 90% purity) as a solid. 'HNMR (400 MHz, DMSO-t/e) δ ppm 8.55 (s, 1H), 8.02 (s, 2H), 6.10 (s, 2H), 3.62 (t, J= 8.0 Hz, 2H), 0.85 (t, J= 8.0 Hz, 2H), 0.09 (s, 9H).
[0198] Step 3: Synthesis of 2-[[7-fluoro-5-[4-[4-methyl-2-(pyridazin-3-yIoxymethyl)thiazol-5yl]thiazol-2-yl]benzotriazol-l-yl]methoxy]ethyl-trimethyl-silane (7c).
(7c)
A mixture of bis(l-adamantyl)-butyl-phosphane (22.55 mg, 62.88 pmol, 0.2 eq) and diacetoxypalladium (14.12 mg, 62.88 pmol, 0.2 eq) in toluene (3 mL) was stirred at 20 °C for 0.5 h under N2 atmosphère. The mixture was added to a mixture of 2-[[5-(4-bromothiazol-2-yl)-7-fluoro-benzotriazol-l-yl]methoxy]ethyltrimethyl-silane 7b (150 mg, 314.41 pmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-l,3,2-dioxaborolane (319.36 mg, 1.26 mmol, 4 eq), CsF (143.27 mg, 943.22 pmol, 34.78 pL, 3 eq), 5-bromo-4-methyl-2-(pyridazin-3-yloxymethyl)thiazole 7a (149.94 mg, 471.61 pmol, 1.5 eq) in MeOH (6 mL) was stirred at 50 °C for 0.5 h, the mixture was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified with prep-HPLC (column: Boston Prime Cl8 150*30mm*5um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 75%-95%, 10min) to give 2-[[7-fluoro-5-[4-[4-methyl-2-(pyridazin-3yloxymethyl)thiazol-5-yl]thiazol-2-yl]benzotriazol-l-yl]methoxy]ethyI-trimethyl-silane 7c (50 mg, 80.98 pmol, 25.8% yield, 90% purity) as a solid. 'HNMR (400 MHz, DMSO-î/ô) <5 ppm 9.09 (dd, J= 1.2,4.4 Hz, 1H), 8.68 (d, J= 1.0 Hz, 1H), 8.28-8.12(m, 2H), 7.83 (dd, J=4.4, 8.8 Hz, 1H), 7.51 (dd, J= 1.2, 8.8 Hz, 1H), 6.22 (s, 2H), 5.92 (s, 2H), 3.74 (t, J= 8.0 Hz, 2H), 2.78 (s, 3H), 0.96 (t, J= 8.0 Hz, 2H), 0.00 (s, 9H).
[0199] Step 3: Synthesis of 5-[2-(7-fluoro-l/7-benzotriazol-5-yl)thiazoI-4-yl]-4-methyl-2(pyridazin-3-yloxymethyl)thiazole (7). A mixture of 2-[[7-fluoro-5-[4-[4-methyl-2-(pyridazin-3yloxymethyl)thiazol-5-yl]thiazol-2-yl]benzotnazol-l-yl]rnethoxy]ethyl-tnmethyl-silane 7c (50 mg, 80.98
μιηοΐ, 1 eq), TB AF (1 M in THF, 1.07 mL, 13.23 eq) in THF (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 60 °C for 12 h. The mixture was concentrated and then water (10 mL) was added. The mixture was extracted with DCM (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na2SC>4, filtered and concentrated. The residue was 5 purified with prep-HPLC (column: Boston Prime C18 150*30mm*5um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 25%-45%, 10min) to give 5-[2-(7-fluoro-l/7-benzotriazol-5yl)thiazol-4-yl]-4-methyl-2-(pyridazin-3-yloxymethyl)thiazole 7 (31.4 mg, 72.37 umol, 89.4% yield, 98.06% purity) as a solid. Ή NMR (400 MHz, DMSO-dÎs) <5 ppm 8.99 (dd, J= 1.4,4.4 Hz, 1H), 8.29 (s, 1H), 8.04 (s, 1H), 7.80 (d, ./= 10.8 Hz, 1H), 7.72 (dd, J= 4.8, 8.8 Hz, 1H), 7.41 (dd, J= 1.4, 8.8 Hz, 1H), 10 5.81 (s, 2H), 2.67 (s, 3H); HPLC (98.06% purity); ES-MS m/z 448.0 [M+23]+.
[0200] Example S8. Préparation of 5-[6-(4,7-difluoro-3H-benzotriazol-5-yl)-2~pyridyl]-4-methyl2-[(5-methyl -pyrimidin-2-yl)oxymethyl]thiazole (8).
General Scheme for Compounds 8,9,12,14, and 15.
'''M
5d
[0201] Step 1: Synthesis of 5-(6-chIoro-2-pyridyl)-4-methyl-2-[(5-methylpyrimidin-2yl)oxymethyl]thiazole (8a).
O
(8a)
To a solution of [5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methanol 5d (1 g, 4.15 mmol, 1 eq) in DMF (10 mL) was added NaH (332.32 mg, 8.31 mmol, 60% purity, 2 eq) at 0°C and stirred for 0.5h, and
2-chloro-5-methyl-pyrimidine ( 1.34 g, 10.39 mmol, 2.5 eq) was added. The mixture was stirred at 20°C for 2h. LCMS showed desired MS was detected. The reaction mixture was poured into ammonium chloride saturated aqueous solution (50 mL) and extracted with ethyl acetate (50 mL*3). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (S1O2, DCM/MeOH=0/l to 10/1) to give 5-(6-chloro-2-pyridyl)-4-methyl-2-[(5-methylpyrimidin-2-yl)oxymethyl]thiazole 8a (0.8 g, 2.40 mmol, 57.86% yield) as a solid. ’H NMR (400 MHz, CHLOROFORM-d) δ = 8.31 (s, 2H), 7.60 (t, J = 7.8 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 5.60 (s, 2H), 2.63 (s, 3H), 2.19 (s, 3H).
[0202] Step 2: Synthesis of 5-[6-(4,7-difluoro-3H-benzotriazol-5-yl)-2-pyridyI]-4-methyl-2-[(5methyl -pyrimidin-2-yl)oxymethyl]thiazole (8). A mixture of 5-(6-chloro-2-pyridyl)-4-methyl-2-[(5methylpyrimidin-2-yl)oxymethyl]thiazole 8a (0.5 g, 1.50 mmol, 1 eq), 4,7-difluoro-6-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl) -IH-benzotriazole (2, Key Intermediate B, 760.08 mg, 2.70 mmol, 1.8 eq), Pd(dppf)Ch (109.93 mg, 150.24 umol, 0.1 eq) and CS2CO3 (1.22 g, 3.76 mmol, 2.5 eq) in dioxane (6 mL) and H2O (2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 100°C for 12 hr under N2 atmosphère. LCMS showed desired MS was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~15% DCM/MeOH ethergradient @ 70 mL/min). The eut fraction was concentrated under reduced pressure to give the crude product. The crude product was purified by triturated with MeOH (10 mL). Then filter cake was collected and concentrated under reduced pressure to give product. The crude product was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0—15% DCM/EA ether gradient @ 50 mL/min). The eut fraction was concentrated under reduced pressure to give 5-[6-(4,7difluoro-3H-benzotriazol-5-yl)-2-pyridyl]-4-methyl-2-[(5-methylpyrimidin-2-yl)oxymethyl]thiazole 8 (250 mg, 553.77 umol, 36.86% yield, 98.20% purity) as a solid. 'H NMR (400 MHz, DMSO-d6) δ = 8.51 (s, 2H), 8.12 - 8.04 (m, 1H), 7.92 (dd, J = 1.5, 7.8 Hz, 1H), 7.86 - 7.75 (m, 2H), 5.64 (s, 2H), 2.71 (s, 3H), 2.21 (s, 3H); HPLC (98.20% purity); ES-MS m/z 452.2 [M+H]+.
[0203] Example S9. Préparation of l-[[5-[6-(4,7-difluoro-3H-benzotriazol-5-yl)-2-pyridyl]-4methyl-thiazoI-2-yl]methoxy]-2-methyI-propan-2-ol (9).
[0204] Step 1: Synthesis of ethyl 2-[[5-(6-chIoro-2-pyridyl)-4-methyl-thiazol-2-yl]methoxy]acetate (9a).
(9a)
A mixture of [5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methanol (from Example S5, mtermediate 5d, 1 g, 4.15 mmol, 1 eq) in DMF (6 mL) cooled to 0 °C was added NaH (332.35 mg, 8.31 mmol, 60% purity, 2 eq) in portions under N2 atmosphère. The mixture was stirred at 0°C for 15 min under N2 atmosphère. Then a solution ethyl 2-bromoacetate (901.92 mg, 5.40 mmol, 597.30 uL, 1.3 eq) was added dropwise to the mixture. The whole mixture was stirred at 0°C for 1 h under N2 atmosphère. Then the whole mixture was stirred at 25°C for 1 h under N2 atmosphère. LCMS showed material was consumed completely and one main peak with desired MS was detected. TLC (PE:EA=1:1) indicated material was consumed completely and one new spot formed. The reaction mixture was quenched by addition NH4CI solution (15 mL) at 0°C, and then extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (30 mL ), dried over Na2SÛ4, filtered and concentrated under reduced pressure to give a residue and purified by flash silica gel chromatography (Eluent of 0~35% Ethyl acetate/Petroleum ether gradient) to give ethyl 2-[[5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methoxy]acetate 9a (600 mg, 1.84 mmol, 44.19% yield) as an oil. Ή NMR (400 MHz, CHLOROFORM-d) δ = 7.70 (t, J= 7.8 Hz, 1H), 7.45 (d, J= 7.5 Hz, 1H), 7.24 (d, J= 7.5 Hz, 1H), 4.92 (s, 2H), 4.30 - 4.20 (m, 4H), 2.71 (s, 3H), 1.31 (t, J= 7.2 Hz, 3H).
[0205] Step 2: Synthesis of l-[[5-(6-chIoro-2-pyridyI)-4-methyl-thiazol-2-yl]methoxy]-2-methylpropan-2-ol (9b).
(9b)
To a solution of ethyl 2-[[5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2-yl]methoxy]acetate 9a (600 mg, 1.84 mmol, 1 eq) in THF (10 mL) at 0°C was added MeMgBr (3 M, 1.84 mL, 3 eq) dropwise. The mixture was stirred at 25°C for 3 h. TLC (PE:EA=0:l) indicated material was consumed completely and one new main spot formed. LCMS showed material was consumed completely and one main peak with desired MS was detected. The reaction mixture was quenched by addition NH4CI saturated solution (5 mL) at 0°C, and then diluted with water (15 mL) and extracted with ethyl acetate (20 mL X 3). The combined organic layers were washed with brine (50 mL), dried over Na2SC>4, filtered and concentrated under reduced pressure to give a residue. Then purified by flash silica gel chromatography (Eluent of 10-40% Ethyl acetate/Petroleum ether gradient) to give l-[[5-(6-chloro-2-pyridyl)-4-methyl-thiazol-2yl]methoxy]-2-methyl-propan-2-ol 9b (350 mg, 1.12 mmol, 60.94% yield) as an oil. 'H NMR (400 MHz,
CHLOROFORM-d) δ = 7.72 (t, J= 7.8 Hz, 1H), 7.47 (d, J= 7.6 Hz, 1H), 7.25 (s, 1H), 4.91 (s, 2H), 3.50 (s, 2H), 2.79 - 2.67 (m, 3H), 1.27 (s, 6H).
[0206] Step 3: Synthesis of l-[[5-[6-(4,7-difluoro-3H-benzotriazol-5-yl)-2-pyridyl]-4-methyIthiazol-2-yl]methoxy]-2-methyI-propan-2-ol (9). A mixture of l-[[5-(6-chloro-2-pyridyl)-4-methylthiazol-2-yl]methoxy]-2 -methyl-propan-2-ol 9b (87 mg, 278.12 umol, 1 eq), 4,7-difluoro-6-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzotriazole (2, Key Intermediate B, 156.34 mg, 556.24 umol, 2 eq), Cs2CO3 (271.85 mg, 834.36 umol, 3 eq) and Pd(dppf)Cl2.CH2Cl2 (113.56 mg, 139.06 umol, 0.5 eq) in dioxane (1 mL)/H2O (0.2 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 105°C for 12 h under N2 atmosphère. LCMS showed material was consumed completely and desired compound was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue and purified by prep-HPLC (basic condition: column: Waters Xbridge Cl8 150*50mm* lOum; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 5%35%,ί 1min). Then re-purified by prep-TLC (SiO2, Ethyl acetate : MeOH = 4:1) to give l-[[5-[6-(4,7difluoro-3H-benzotriazol-5-yl)-2-pyridyl]-4-methyl-thiazol-2-yl]methoxy]-2-methyl-propan-2-ol 9 (35 mg, 77.79 umol, 6.99% yield, 95.9% purity) as a solid. ’HNMR (400 MHz, DMSO-d6) δ = 8.10 - 8.03 (m, 1H), 7.91 (dd, J = 1.4, 7.9 Hz, 1H), 7.81 - 7.74 (m, 2H), 4.80 (s, 2H), 4.47 (s, 1H), 3.36 (br s, 2H), 2.69 (s, 3H), 1.13 (s, 6H); HPLC (95.91% purity); ES-MS m/z 432.4 [M+H]+.
[0207] Example S10. Préparation of 23,6-trifluoro-4-[4-[4-methyl-2-(pyrimidin-2yloxymethyl)thiazol-5-yl]thiazol-2-yl]phenoI (10).
[0208] Step 1: Synthesis of 5-bromo-4-methyl-2-(pyrimidin-2-yloxymethyl)thiazole (10a).
[0209] To a mixture of (5-bromo-4-methyl-thiazol-2-yl)methanol 3e (500 mg, 2.40 mmol, 1 eq) in THF (12.5 mL) was added NaH (144.00 mg, 3.60 mmol, 60% purity, 1.5 eq) at 0°C and purged with N2 for 3 times, and then the mixture was stirred at 15°C for 0.5 h. 2-chloropyrimidine (329.86 mg, 2.88 mmol, 1.2 eq) was added to the reaction mixture, the mixture was stirred at 15°C for 12 h. TLC (PE/EtOAc=2:l) showed a new spot was formed, and the desired MS was observed on LCMS. The reaction mixture was poured into ice-water (30 mL), extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried overNa2SC>4, filtered and concentrated. The residue was purified by clumn chromatography (SiO2, PE/EtOAc=4:l) to give 5-bromo-4-methyl-2-(pyrimidin-221204 yloxymethyl)thiazole 10a (534 mg, 1.87 mmol, 77.76% yield) as a solid. 'H NMR (400 MHz,
CHLOROFORM-d) δ = 8.58 (d, J = 4.6 Hz, 2H), 7.03 (t, J = 4.8 Hz, 1H), 5.63 (s, 2H), 2.41 (s, 3H).
[0210] Step 2: Synthesis of 2,3,6-trifluoro-4-[4-[4-methyl-2-(pyrimidin-2-yloxymethyl)thiazol-5yl]thiazol-2-yl]phenol (10). A mixture of bis(l-adamantyl)-butyl-phosphane (62.44 mg, 174.14 mol, 0.2 eq) and Pd(OAc)2 (19.55 mg, 87.07 pmol, 0.1 eq) in anhydrous toluene (30 mL) was stirred at 20 °C for 0.5 h under N2 atmosphère. The above solution was added to a mixture of 4-(4-bromothiazol-2-yl)-2,3,6trifluoro-phenol (4, Key Intermediate D, 300 mg, 870.71 pmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5tetramethyl-l,3,2-dioxaboro!an-2-yl)-l,3,2-dioxaborolane (884.43 mg, 3.48 mmol, 4 eq), CsF (396.78 mg, 2.61 mmol, 96.31 pL, 3 eq), 5-bromo-4-methyl-2-(pyrimidin-2-yloxymethyl)thiazole 10a (332.20 mg, 1.04 mmol, 1.2 eq) in anhydrous MeOH (100 mL) and then the mixture was stirred at 80 °C for 12 h under N2 atmosphère. The reaction mixture was concentrated and then water (200 mL) was added. The mixture was extracted with DCM (200 mL x 3). The combined organic layers were washed with brine (200 mL), dried over NaiSOi, fïltered and concentrated. The residue was purified with prep-HPLC (colurnn: Boston Prime C18 150*30mm*5um;mobile phase: [water(0.2%FA)-ACN]; B%: 46%69%, 10min) to give 2,3,6-trifluoro-4-[4-[4-methyl-2-(pyrimidin-2-yloxymethyl)thiazol-5-yl]thiazol-2yl]phenol 10 (49 mg, 110.03 pmol, 12.6% yield, 98% purity) of this batch as a solid. ’H NMR (400MHz, DMSO-rfô) δ ppm 8.70 (d, J= 4.8 Hz, 2H), 8.03 (s, 1H), 7.75-7.71 (m, 1H), 7.25 (t, J= 4.8 Hz, 1H), 5.66 (s, 2H), 2.63 (s, 3H); HPLC (100.00% purity); ES-MS m/z 437.1 [M+H]+.
[0211] Example SU. Préparation of 23,6-trifluoro-4-[4-[4-methyl-2-(2pyridyloxymethyl)thiazol-5-yl]thiazol-2-yl]phenol (11).
[0212] Step 1: Synthesis of 5-bromo-4-methyl-2-(2-pyridyloxymethyl)thiazole (lia).
(11a)
To a solution of (5-bromo-4-methyl-thiazol-2-yl)methanol 3e (0.4 g, 1.73 mmol, 1 eq) and pyridin-2-ol (329.07 mg, 3.46 mmol, 2 eq) in THF (4 mL) were added DEAD (602.64 mg, 3.46 mmol, 629.06 mL, 2 eq) and PPI13 (907.60 mg, 3.46 mmol, 2 eq) under N2. The reaction mixture was stirred at 20 °C for 1 h under N2. The reaction mixture was concentrated under reduced pressure. The residue was purified with flash silica gel chromatography (ISCO®; 20 g SepaFIash® Silica Flash Colurnn, Eluent of 0~35%
Ethylacetate/Petroleum ether gradient @ 35 mL/min) to give 5-bromo-4-methyl-2-(2pyridyloxymethyl)thiazole lia (130 mg, 410.30 mmol, 23.7% yield, 90% purity) as a solid. 'HNMR (400 MHz, CDCh) δ ppm 8.22-8.14 (m, 1H), 7.65-7.57 (m, 1H), 6.96-6.91 (m, 1H), 6.83 (d, J = 8.4 Hz, 1H), 5.57 (s, 2H), 2.40 (s, 3H).
[0213] Step 2: Synthesis of 2,3,6-trifluoro-4-[4-[4-methyl-2-(2-pyridyloxymethyl)thiazol-5yl]thiazol-2-yl] phénol (11). A mixture of bis(l-adamantyl)-butyl-phosphane (31.22 mg, 87.07 mol, 0.2 eq) and diacetoxypalladium (19.55 mg, 87.07 umol, 0.2 eq) in toluene (6 mL) was stirred at 20 °C for 0.5 h under N2 atmosphère, the mixture was added to a mixture of 5-bromo-4-methyl-2-(2pyridyloxymethyl)thiazole lia (169.88 mg, 565.96 mol, 1.3 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (442.21 mg, 1.74 mmol, 4 eq), CsF (198.39 mg, 1.31 mmol, 48.15 pL, 3 eq), 4-(4-bromothiazol-2-yl)-2,3,6-trifluoro-phenol (4, Key Intermediate D, 150 mg, 435.36 mol, 1 eq) in MeOH (4 mL), the mixture was stirred at 80 °C for 1 h under microwave (2 bar). The mixture was concentrated and then water (50 mL) was added. The mixture was extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na2SC>4, fïltered and concentrated. The residue was purifïed with prep-HPLC (column: YMC-Actus Triart Cl8 150*30mm*7um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 14%-54%,11 min) to give the crude product. The crude product was purifïed with prep-HPLC (column: Phenomenex Gemini-NX 150*30mm*5um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 12%52%, 10min) to give 2,3,6-trifluoro-4-[4-[4-methyl-2-(2-pyridyloxymethyl)thiazol-5-yl]thiazol-2yl]phenol 11 (27.6 mg, 63.01 umol, 14.5% yield, 99.41% purity) as a solid. Ή NMR (400 MHz, DMSOdf,) 5ppm 11.67 (br s, 1H), 8.23 (dd, J= 1.6,4.8 Hz, 1H), 8.01 (s, 1H), 7.83-7.67 (m, 2H), 7.07 (dd, J= 5.6, 6.8 Hz, 1H), 6.98 (d, J= 8.4 Hz, 1H), 5.62 (s, 2H), 2.63 (s, 3H); HPLC (Purity: 99.41%); ES-MS m/z 341.0 [M+H]+.
[0214] Example S12. Préparation of 3-fluoro-2-hydroxy-5-[6-[4-methyI-2-(pyrimidin-2yloxymethyl)thiazol-5-yl]-2-pyridyl]benzonitrile (12).
[0215] Step 1: Synthesis of 3-fluoro-2-hydroxy-benzonitrile (12a).
F
(12a)
To a solution of 2,3-difluorobenzonitrile (500 mg, 3.59 mmol, 400.00 pL, 1 eq) in DMF (15 mL) was added 2-methylsulfonylethanol (446.29 mg, 3.59 mmol, 1 eq) and NaH (287.53 mg, 7.19 mmol, 60% purity, 2 eq) in small portions at 25 °C. The reaction mixture was stirred at 25 °C for 0.5 h. The reaction mixture was poured into water (30 mL) and washed with ethyl acetate (30 mL x 3), the aqueous phase was adjusted with pH = 2 with 1 N HCl and extracted with ethyl acetate (30 mL x 3). The combined organic layers were dried over Na2SC>4, filtered, fïltrate was concentrated under reduced pressure to give 3-fluoro-2-hydroxy-benzonitrile 12a (350 mg, 2.30 mmol, 63.9% yield, 90% purity) as a solid. Ή NMR (400 MHz, DMSO-Jô) δ ppm 11.45 (br s, 1H), 7.54-7.44 (m, 1H), ΊΑΊ-ΊΑ2 (m, 1H), 6.94 (dt, J= 4.8, 8.0 Hz, 1H).
[0216] Step 2: Synthesis of 5-bromo-3-fluoro-2-hydroxy-benzonitrile (12b).
OH (12b)
To a solution of 3-fluoro-2-hÿdroxy-benzonitrile 12a (350 mg, 2.30 mmol, 1 eq) in CH3CN (5 mL) was added NBS (449.78 mg, 2.53 mmol, 1.1 eq) in one portion at 20 °C. The reaction mixture was stirred at 20 °C for 1 h. The reaction mixture was poured into sat. Na2CC>3 (20 mL) and washed with ethyl acetate (20 mL x 3). Then the aqueous phase was adjusted to pH = 2 with 1 N HCl and extracted with ethyl acetate (20 mL x 3), the combined organic layers were dried over Na2SO4, filtered, fïltrate was concentrated to give 5-bromo-3-fluoro-2-hydroxy-benzonitrile 12b (300 mg, 1.19 mmol, 52.0% yield, 86% purity) as a solid. ‘H NMR (400 MHz, DMSO-î/6) δ ppm 11.87 (br. s, 1H), 7.88-7.85 (m, 1H), 7.77 (d, J= 1.6 Hz, 1H).
[0217] Step 3: Synthesis of 3-fluoro-2-hydroxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2yl)benzonitrile (12c).
(12c)
A mixture of 5-bromo-3-fluoro-2-hydroxy-benzonitrile 12b (250 mg, 995.34 pmol, 1 eq), 4,4,5,5tetramethyl-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (631.88 mg, 2.49 mmol, 2.5 eq), KOAc (293.05 mg, 2.99 mmol, 3 eq) and Pd(dppf)Ch.CH2C12 (81.28 mg, 99.53 pmol, 0.1 eq) in 1,4-dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 85 °C for 12 h under N2 atmosphère. TLC (petroleum ether/ethyl acetate = 1/1) showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to give 3-fluoro-2-hydroxy-521204
(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzonitrile 12c (300 mg, crude) as a gum. 'HNMR(400 MHz, CDCh) δ ppm 7.75 (s, 1H), 7.64 (d, J= 10.4 Hz, 1H), 7.43-7.38 (m, 1H), 1.33 (s, 12H).
[0218] Step 4: Synthesis of 3-fluoro-2-hydroxy-5-[6-[4-methyl-2-(pyrimidin-2yloxymethyI)thiazoI-5-yl]-2-pyridyI]benzonitriIe (12). A mixture of 5-(6-chloro-2-pyridyI)-4-methyI5 2-(pyrimidin-2-yIoxymethyl)thiazole (5, Key Intermediate E, 250 mg, 705.81 pmol, 1 eq), 3-fluoro-2hydroxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzonitrile 12c (278.52 mg, 1.06 mmol, 1.5 eq), CS2CO3 (459.94 mg, 1.41 mmol, 2 eq) and Pd(dppf)C12.CH2C12 (57.64 mg, 70.58 pmol, 0.1 eq) in 1,4dioxane (9 mL) and H2O (3 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 85 °C for 12 h under N2 atmosphère. The reaction mixture was concentrated under reduced pressure. The residue was purifïed with reversed-phase HPLC (H2O-ACN condition) to give crude product, which was purifïed with prep-HPLC (column: Boston Prime C18 150*30mm*5pm; mobile phase: [water (0.05%NH3H20+10mMNH4HC03)-ACN]; B%: 27%-50%,7min) to give 3-fluoro-2hydroxy-5-[6-[4-methyl-2-(pyrimidin-2-yloxymethyl)thiazol-5-yl]-2-pyridyl]benzonitrile 12 (71.8 mg, 166.89 pmol, 23.6% yield, 97.49% purity) as a solid. ’HNMR (400 MHz, DMSO-dô) <5 ppm 8.69 (d, J=
4.8 Hz, 2H), 7.79 (d, J= 2.4 Hz, 1H), 7.78-7.75 (m, 1H), 7.76 (d, J= 7.6 Hz, 1H), 7.75-7.70 (m, 1H),
7.67 (d, J= 8.0 Hz, 1H), 7.40 (d, J= 7.6 Hz, 1H), 7.23 (t, J= 4.8 Hz, 2H), 5.64 (s, 2H), 2.66 (s, 3H); HPLC (Purity: 97.49%); ES-MS m/z 420.2 [M+H]+.
[0219] Example S13. Préparation of methyl((4'-methyl-2-(4-((phenylsulfonyl)carbamoyI)phenyl)[4,5'-bithiazol]-2'-yl)methyl)carbamate (13).
General Scheme for Compounds 13 and 16.
F
[0220]
Step 1: Synthesis of 4-bromo-7V-(phenylsulfonyI)benzamide (13a).
(13a)
[0221] To a solution of 4-bromobenzoyl chloride (3 g, 13.67 mmol, 1 eq) and benzenesulfonamide (2.36 g, 15.04 mmol, 1.1 eq) in DCM (30 mL) was added DIEA (5.30 g, 41.01 mmol, 7.14 mL, 3 eq). The mixture was stirred at 25 °C for 2 h. TLC (PE/EtOAc = 1/1) indicated starting material was consumed completely, and one major new spot with larger polarity was formed. The mixture was added H2O (10 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with H2O (100 mL x 3) and brine (100 mL x 2), dried over Na2SO4, filtered and concentrated. The residue was purifïed by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0—50% Ethyl acetate/Petroleum ether gradient @ 40 mL/min) to give 7V-(benzenesulfonyl)-4-bromo-benzamide 13a (4.5 g, 11.91 pmol, 87.1% yield, 90% purity) as a solid. 'H NMR (400 MHz, DMSO-î/î) <5 ppm 7.867.80 (dd, J= 8, 12 Hz, 4H), 7.53 (d, J= 8.4 Hz, 2H), 7.40-7.47 (d, J= 5.6 Hz, 3H).
[0222] Step 2: Synthesis of/V-(phenylsuIfonyl)-4-(4,4,5,5-tetramethyI-l,3,2-dioxaborolan-2yl)benzamide (13b).
(13b)
[0223] A mixture of/V-(benzenesulfonyI)-4-bromo-benzamide 13a (5.2 g, 13.76 mmol, 1 eq), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (6.99 g, 27.51 mmol, 2 eq), Pd(dppf)Ch (1.01 g, 1.38 mmol, 0.1 eq), KOAc (2.70 g, 27.51 mmol, 2 eq) in dioxane (100 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 °C for 12 h under N2 atmosphère. TLC (PE/EtOAc = 1/1) indicated starting material was consumed completely, and one major new spot with lower polarity was formed. The mixture was concentrated and then water (100 mL) was added. The mixture was extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered and concentrated. The residue was purifïed by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ether gradient @ 40 mL/min) to give 7V-(benzenesulfonyl)-4-(4,4,5,5-tetramethyl-l,3,2 dioxaborolan-2-yl)benzamide 13b (5.9 g, 13.71 mmol, 99.7% yield, 90% purity) as a solid. Ή NMR (400MHz, CDCh) δ ppm 8.17 (d, J= 8 Hz, 2H), 7.89-7.83 (m, 2H), 7.80-7.74 (m, 2H), 7.66 (s, 1H), 7.597.53 (m, 2H), 1.34 (s, 12H).
[0224] Step 3: Synthesis of 4-(4-bromothiazol-2-yI)-7V-(phenyIsulfonyl)benzamide (13c).
(13c)
A mixture of7V-(benzenesulfonyl)-4-bromo-benzamide 13b (500 mg, 1.32 pmol, 1 eq), 4,4,4',4',5,5,5',5'octamethyl-2,2'-bi(l,3,2-dioxaborolane) (671.81 mg, 2.65 pmol, 2 eq), Pd(dppf)Ch (96.79 mg, 132.28 pmol, 0.1 eq), KOAc (259.64 mg, 2.65 pmol, 2 eq) in dioxane (10 mL) was degassed and purged with N2 for 3 times, and then the mixture was stirred at 80 °C for 12 h under N2 atmosphère. TLC (ΡΕ/EtOAc = 1/1) indicated starting material was remained, and one major new spot with lower polarity was formed. The mixture was concentrated and then water (10 mL) was added. The mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na2SÛ4, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-50% Ethyl acetate/Petroleum ether gradient @ 25 mL/min) to give N(benzenesulfonyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzamide 13c (510 mg, 1.19 pmol, 89.6% yield, 90% purity) as a solid. '11 NMR (400 MHz, DMSO-î/6) δ ppm = 8.05-7.92 (m, 5H), 7.887.47 (m, 5H).
[0225] Step 4: Synthesis of methyI((4'-methyI-2-(4-((phenylsulfonyI)carbamoyl)phenyl)-[4,5'bithiazol]-2'-yl)methyl)carbamate (13). A solution of bis(l-adamantyl)-butylphosphane (45.74 mg, 127.57 pmol, 0.2 eq) and diacetoxypalladium (28.64 mg, 127.57 pmol, 0.2 eq) in toluene (17.5 mL) was stirred at 20 °C for 0.5 h under N2. The mixture was added to a solution of N-(benzenesulfonyl)-4-(4bromothiazol-2-yl)benzamide 13c (300 mg, 637.84 pmol, 1 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (647.89 mg, 2.55 mmol, 4 eq), methyl N-[(5bromo-4-methyl-thiazol-2-yl)methyl]carbamate 16a (263.06 mg, 892.98 pmol, 1.4 eq) and CsF (290.67 mg, 1.91 mmol, 70.55 pL, 3 eq) in MeOH (30 mL) at 50 °C under N2. The mixture was stirred at 80 °C for 12 h. The mixture was concentrated and then DMSO (4 mL) was added. The mixture was filtered and the fïltrate was purified by prep-HPLC (column: YMC-Triart Prep C18 150*40mm*7um;mobile phase: [water(0.225%FA)-ACN];B%: 45%-75%,8min) to give methyl N-[[5-[2-[4(benzenesulfonylcarbamoyl)phenyl]thiazol-4-yl]-4-methyl-thiazol-2-yl]methyl]carbamate 13 (31.7 mg, 59.04 pmol, 9.3% yield, 98.45% purity) as a solid. Ή NMR (400 MHz, DMSO-cfe) δ ppm 8.07 (d, J= 6.8
Hz, 3H), 8.05-7.97 (m, 5H), 7.76-7.69 (m, 1H), 7.69-7.61 (m, 2H), 4.42 (d, J= 4.0 Hz, 2H), 3.60 (s, 3H), 2.60 (s, 3H); HPLC (98.45% purity); ES-MS m/z 529.1 [M+H]+.
[0226] Example S14. Préparation of 5-(6-(lH-benzo[d] [1,2,3]triazol-6-yl)pyridin-2-yl)-4-methyl2-((pyrimidin-2-yloxy)methyl)thiazole (14). To a 2.0 mL microwave tube was added 5-(6chloropyridin-2-yl)-4-methyl-2-((pyrimidin-2-yloxy)methyl)thiazole (5, Key Intermediate E, 80 mg, 250.96 pmol), 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d][l,2,3]triazole (67.66 mg, 276.05 pmol), potassium carbonate (34.68 mg, 250.96 pmol), water (0.5 ml) and dioxane (1.5 ml). PdCh(dppf) (18.36 mg, 25.10 pmol) was finally added and the vial sealed and heated to 80 °C with stirring. After a total of 26 hr., the mixture was allowed to cool to room temp and then diluted with water and extracted with EtAc. The extracts were then washed once with water followed by brine solution, dried (Na2SO4), filtered and concentrated in vacuo. The crude product was chromatographed (ISCO, dry loading, 4g silica column, gradient = 60% EtAc/heptane to 100% EtAc, 18 min run time). The fractions containing product were then concentrated in vacuo to give 5-(6-(lH-benzo[d][l,2,3]triazol-6-yl)pyridin2-yl)-4-methyl-2-((pyrimidin-2-yloxy)methyl)thiazole 14 (10 mg, 24.91 pmol, 9.9 % yield) as a solid. Ή NMR (400 MHz, DMSO-d6) δ 15.88 (s, 1H), 8.70 (d, J = 4.7 Hz, 3H), 8.41 - 7.94 (m, 4H), 7.73 (d, J = 7.7 Hz, 1H), 7.24 (t, J = 4.8 Hz, 1H), 5.68 (s, 2H), 2.73 (s, 3H). ES-MS m/z 402.4 [M+H]+.
[0227] Example S15. Préparation of 3-(4-(6-(4-methyl-2-((pyrimidîn-2-yloxy)methyl)thiazol-5yl)pyridin-2-yl)phenyl)-l,2,4-oxadiazol-5(4H)-one (15).
[0228] Step 1: Synthesis of 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)-l,2,4oxadiazol-5(4H)-one (15a).
O
(15a)
In a 5 mL microwave vial were placed bis(pinacolato)diboron (702.33 mg, 2.74 mmol), 3-(4bromophenyl)-l,2,4-oxadiazol-5(4H)-one (330 mg, 1.37 mmol), potassium acetate (537.44 mg, 5.48 mmol) and DMSO (5 mL). After the mixture was purged with nitrogen for 5 min, PdCh(dppf) (75.13 mg, 102.68 pmol) was added at 20 °C. After 20 h at 80 °C, the mixture was poured into water (30 mL), stirred for 30 min, filtered, and dried to give 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)21204
l,2,4-oxadiazol-5(4H)-one 15a (540 mg, 1.87 mmol, 136.9 % yield), which was used in the next step without further purification. ES-MS m/z 289.2 [M+H]+.
[0229] Step 2: Synthesis of 3-(4-(6-(4-methyl-2-((pyrimidin-2-yIoxy)methyl)thiazol-5-yl)pyridin2-yl)phenyl)-l,2,4-oxadiazol-5(4H)-one (15). In a 5 mL microwave vial were placed 5-(65 chloropyridin-2-yl)-4-methyl-2-((pyrimidin-2-yloxy)methyl)thiazole (5, Key Intermediate E, 30 mg, 94.11 pmol), 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)-l,2,4-oxadiazol-5(4H)-one 15a (54.23 mg, 188.22 pmol), césium carbonate (76.66 mg, 235.27 pmol), water (0.6 ml), and 1,4-dioxane (3 ml). After the mixture was bubbled with nitrogen gas for 5 min, PalladiumTetrakis (10.88 mg, 9.41 pmol) was added at 20 °C. After 15 h at 90 °C, the mixture was diluted with EtOAc (20 mL) and water 10 (10 mL), and acidified with 10% citric acid. The organic layer was separated, dried (Na2SÜ4), filtered, and concentrated in a rotavap to give a residue, which was purified by HPLC to afford 3-(4-(6-(4-methyl2-((pyrimidin-2-yloxy)methyl)thiazol-5-yl)pyridin-2-yl)phenyl)-l,2,4-oxadiazol-5(4H)-one 15 (9.2 mg, 20.70 pmol, 22.0 % yield) as a solid after lyophilization. ’H NMR (400 MHz, DMSO-d6) δ 8.72 (d, J = 4.8 Hz, 2H), 8.32 (d, J = 8.2 Hz, 2H), 8.06 (d, J = 5.8 Hz, 2H), 7.98 (d, J = 8.2 Hz, 2H), 7.77 (dd, J = 5.8, 15 2.8 Hz, 1H), 7.26 (t, J = 4.8 Hz, 1H), 5.70 (s, 2H), 2.74 (s, 3H), 2.56 (s, 1H). ES-MS m/z 445.3 [M+H]+.
[0230] Example S16. Préparation of methyl N-[[5-[2-(4,7-difluoro-lH-benzotriazol-5-yl)thiazol-4yl]-4-methyl-thiazol-2-yI]methyl]carbamate (16).
[0231] Step 1: Synthesis of methyl N-[(5-bromo-4-methyl-thiazol-2-yl)methyl]carbamate (16a).
(16a)
To a solution of (5-bromo-4-methyl-thiazol-2-yl)methanamine (3, Key Intermediate C, 1 g, 4.83 mmol, 1 eq) in DCM (20 mL) was added TEA (2.44 g, 24.14 mmol, 3.36 mL, 5 eq) and methyl chloroformate (1.37 g, 14.49 mmol, 1.12 mL, 3 eq) at 0°C. The mixture was stirred at 25°C for 2 hr. LCMS showed the desired mass was detected. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was poured into ammonium chloride saturated aqueous solution (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0-70% Ethylacetate/Petroleum ethergradient @ 20 mL/min). The eut fraction was concentrated under reduced pressure to give methyl N-[(5-bromo-4-methyl-thiazol-2-yl)methyl]carbamate 16a (440 mg, 1.66 mmol, 34.37% yield) was obtained as a solid. Ή NMR (400MHz, CHLOROFORM-d) 7.26 (s, 1H), 5.46 - 5.22 (m, 1H), 4.55 (br d, J=6.0 Hz, 2H), 3.72 (s, 3H), 2.36 (s, 3H).
[0232] Step 2: Synthesis of methyl N-[[5-[2-[4,7-difluoro-l-(2trimethylsilylethoxymethyl)benzotriazol-5-yl]thiazoI-4-yl]-4-methyl-thiazol-2-yI]methyl]carbamate (16b).
HN
F (16b)
A mixture of Pd(OAc)2 (19.07 mg, 84.94 umol, 0.1 eq) and bis(l-adamantyl)-butyl-phosphane (60.91 mg, 169.88 umol, 0.2 eq) in Toi. (8 mL) was stirred at 20°C for 0.5 h under N2. The above mixture was added to a mixture of 2-[[5-(4-bromothiazoI-2-yI)-4,7-difluoro-benzotriazol-l-yl]methoxy]ethyl-trimethyl-silane (6, Key Intermediate F, 380 mg, 849.40 umol, 1 eq), methyl N-[(5-bromo-4-methyl-thiazol-2yl)methyl]carbamate 16a (270.24 mg, 1.02 mmol, 1.2 eq), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyll,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (862.79 mg, 3.40 mmol, 4 eq) and CsF (387.07 mg, 2.55 mmol, 93.95 uL, 3 eq) in MeOH (32 mL). The mixture was taken up into a microwave tube. The sealed tube was heated at 80°C for 1 h under microwave under N2. TLC indicated one new spot formed. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purifîed with flash silica gel chromatography (ISCO®; 20 g SepaFlash ® Silica Flash Column, Eluent of 0~100% PE/EA gradient @ 75mL /min) to give methyl N-[[5-[2-[4,7-difluoro-l-(2trimethylsilylethoxymethyl)benzotriazol-5-yl]thiazol-4-yl]-4-methyl-thiazol-2-yl]methyl]carbamate 16b (110 mg, 199.03 umol, 23.43% yield) as a solid.
[0233] Step 3: Synthesis of methyl N-[[5-[2-(4,7-difluoro-lH-benzotriazol-5-yl)thiazol-4-yl]-4methyl- thiazol-2-yl]methyl]carbamate (16). To a solution of methyl N-[[5-[2-[4,7-difluoro-l-(2trimethylsilylethoxymethyl)benzotriazol-5-yl]thiazol-4-yl]-4-methyl-thiazol-2-yl]methyl]carbamate 16b (100 mg, 180.93 umol, 1 eq) in DCM (5 mL) was added TFA (3.08 g, 27.01 mmol, 2.00 mL, 149.29 eq) at 0°C, and the mixture was stirred at 20°C for 2h. LCMS showed desired MS was detected. The reaction mixture was concentrated under reduced pressure to give a residue and purifîed by prep-HPLC (column: Welch Xtimate C18 150*30mm*5um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%:
10%-40%,l 1.5min), and was further purified by prep-HPLC (column: Welch Xtimate Cl8 150*30mm*5um;mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B%: 10%-40%,l 1.5min) to give methyl N-[[5-[2-(4,7-difluoro-lH-benzotriazol-5-yl)thiazol-4-yl]-4-methyl-thiazol-2yl]methyl]carbamate 16 (26 mg, 61.55 umol, 34.02% yield, 99.67% purity) as a solid. ’H NMR (400 MHz, DMSO-de) δ = 8.16 - 8.04 (m, 2H), 7.92 (dd, J= 4.4, 10.5 Hz, 1H), 4.44 (d, J= 6.1 Hz, 2H), 3.62 (s, 3H), 2.62 (s, 3H), HPLC (99.67% purity); ES-MS m/z 423.0 [M+H]+.
[0234] Example S17. Compounds 17-212 were prepared in accordance with the procedures described in Examples S7-S16 using suitable reagents and modifications as would be known by a person of skill in the art.
[0235] Compounds described herein may be prepared according to the methods and examples as described herein and were characterized using standard techniques known in the art, such as ’H NMR and mass spectra.
Biological Examples
[0236] Example Bl. BPGM Synthase Assay.
[0237] Materials
[0238] The following materials were used in this assay: deionized water; Bisphosphoglycerate mutase (BPGM; Standard Buffer: 50 mM Tris, 0.01% Tween 20, pH 7.4); BPGM Reaction Buffer (50 mM Tris, 0.01% Tween 20,3.23 mM KH2PO4, pH 7.4); dithiothreitol (DTT; Stock solution: 100 mM in Standard Buffer); 384-Well Black Assay Plate (Corning, P/N 3575); DMSO; BPGM Stock Solution (500 nM in BPGM Standard Buffer); Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Stock Solution: 40 U/mL in 20 mM Tris-HCL Buffer with 20% Glycerol, ImM EDTA, 1 mM DTT); Glyceraldehyde 3phosphate (GAP; Stock Solution: 20 mM in BPGM Standard Buffer); 3-PG Stock Solution (500 μΜ in BPGM Standard Buffer); Nicotinamide adenine dinucleotide (NAD; Stock Solution: 50 mM in BPGM Standard Buffer); Koningic Acid (1 mM Stock in DMSO); Resazurin Stock Solution (10 mM in DMSO); Diaphorase Stock Solution (40 U/mL in BPGM Standard Buffer); DTT Reaction Buffer (1 mM DTT in BPGM Reaction Buffer); Enzyme Solution (5 nM BPGM, 0.4 U/mL GAPDH in DTT Reaction Buffer); GAPDH Solution (0.4 U/mL GAPDH in DTT Reaction Buffer); Substrate Solution (2 mM NAD, 20 μΜ 3PG, 800 μΜ GAP in DTT Reaction Buffer); and Resazurin Solution (5 U/mL Diaphorase, 500 μΜ Resazurin in BPGM Standard Buffer).
[0239] Procedures
[0240] To the assay plate was added Enzyme Solution (20 uL) to columns 2-22 and 24 of the assay plate. To columns 1 and 23 was added GAPDH Solution (20 uL). A separate compound plate was prepared at the desired concentrations and ail wells were normalized with 5% DMSO. The compound plate was incubated for 30 minutes at RT. Next, the substrate solution (20 pL) was dispensed to ail reaction wells and the plate was incubated for 60 minutes at RT. Koningic acid (1 pL) was added and the plate was incubated for 10 minutes at RT. During this time period, the NADH fluorescence was read at ex: 360 / em: 460. Next, Resazurin Solution (10 pL) was added to ail reaction wells and the plate was incubated for 30 minutes at RT. The resorufm fluorescence was then read at ex:544/em:590.
[0241] The results of the BPGM synthase assay for select exemplary compounds are shown in Table 3. Table 3. hBPGM Synthase IC50 Values for Exemplary Compounds.
Compound No. | hBPGM Synthase IC50 (nM) |
7 | 92 |
8 | 21 |
9 | 19 |
10 | 159 |
11 | 511 |
12 | 256 |
13 | 169 |
14 | 1010 |
15 | 138 |
16 | 50 |
[0242] Example B2. BPGM Phosphatase Assay.
[0243] Materials
[0244] The following materials were used in this assay: Tris buffer (50 mM Tris, 0.01% Tween 20, pH 7.4); cyclohexylammonium sait of 2,3-BPG (stock solution of 500 mM in ultapure distilled water; human Bisphosphoglycerate mutase (hBPGM; stock solution of 110 pM in Standard Buffer); 3-Phosphoglyceric acid (3-PG; stock solution of 100 mM in ultrapure distilled water); 384-Well Polystyrène Plates (Fisherbrand™, CatalogNo.: 12-566-625); BIOMOL GREEN REAGENT (Enzo life sciences, BMLAK111-0250); and 1 mM DMSO stock of exemplary compounds.
[0245] Procedures (0246] A 3-PG enzyme mix solution (final enzyme concentration 62.5 nM, 3-PG concentration at 50 pM, 14.5 uL) was added to onto a 384-well clear plate. Solutions of the test compounds were then added to the plate and the DMSO content was normalized across the plate. The plate was incubated at RT for 15 min. Next, the substrate 2,3-BPG (5 pL) was added to ail the wells, and the plate was sealed and incubated for 24 hr at RT. After incubation, BIOMOL green dye (40 pL) was added to ail the wells, the plate was shaken to mix, and the plate was incubated at RT for 20-30 min. Absorbance measurements were recorded at 620 nm.
[0247] Results
[0248] The results of the BPGM phosphatase assay for select exemplary compounds are shown in
Table 4.
Table 4. hBPGM Phosphatase ECso Values for Exemplary Compounds.
Compound No. | hBPGM Phosphatase ECso (nM) |
7 | 55 |
8 | 40 |
10 | 310 |
11 | 190 |
13 | 55 |
14 | 570 |
15 | 170 |
[0249] Example B3. Human Cell-Based Assay.
[0250] Materials
[0251] The following materials were used in this assay: DMSO; Hemox buffer (30 mM TES, 135 mM NaCl, 5mM KC1, pH 7.4); Inosine (100 mM in hemox buffer); Glucose (1 M in water); human red blood cells; LC/MS Optima grade methanol; LC/MS Optima grade water; and Incubation buffer (30 mM TES, 135 mM NaCl, 5mM KC1, 50 mM inosine, 20 mM glucose pH 7.4).
[0252] Procedures
[0253] Test compounds were loaded onto a 96-well plate (final concentration of DMSO was 1%). 10 mL whole blood was resuspended with an équivalent amount of 2X incubation buffer to make 25% hct & 50% plasma solution. The final solution contains 10 mM glucose and 25 mM inosine. The blood suspension (100 uL) was added to the wells of the plate. The plate was covered with an adhesive foil cover and plastic lid, and incubated at 37 °C for 24 h. The samples were extracted through an SPE column and the métabolites (2,3-BPG, ATP) were analyzed by LC/MS.
[0254] Results
[0255] The results of the cell-based assay for a select exemplary compound is shown in Table 5.
Table 5. hRBC ECso Values for Exemplary Compounds.
Compound No. | hRBC ECso (μΜ) |
16 | 22.5 |
[0256] Additional results from the hBPGM synthase and hBPGM phosphate assays as described herein are shown in Table 6.
Table 6. Additional Assay Results
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
7 | 5.50E-08 | 9.20E-08 |
8 | 4.00E-08 | 1.70E-08 |
9 | 1.90E-08 | |
10 | 3.10E-07 | 1.30E-07 |
11 | 1.90E-07 | 5.10E-07 |
12 | 2.60E-07 | |
13 | 3.20E-08 | 1.70E-07 |
15 | 1.70E-07 | 1.40E-07 |
24 | 2.50E-07 | |
25 | 4.40E-06 | |
26 | 1.10E-07 | |
27 | 1.50E-06 | |
28 | 1.60E-06 | |
29 | 5.70E-06 | |
30 | 2.00E-07 | |
31 | 3.50E-08 | |
32 | 7.60E-08 | |
33 | 2.50E-07 | |
34 | 2.50E-07 | |
35 | 6.00E-07 | |
36 | 1.30E-06 | |
37 | 1.30E-05 | |
38 | 3.60E-08 | |
39 | 4.10E-08 | |
40 | 4.40E-08 | |
41 | 7.50E-08 | |
42 | 4.10E-06 | |
43 | 1.40E-08 | |
44 | 2.50E-08 | |
45 | 4.80E-08 |
Compound No. | huBPGM: phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
46 | 1.30E-07 | |
47 | 2.50E-08 | |
48 | 3.10E-08 | |
49 | 4.70E-08 | |
50 | 7.40E-08 | |
51 | 2.80E-07 | |
52 | 3.90E-07 | |
53 | 8.90E-07 | |
54 | 9.10E-08 | |
55 | 2.20E-07 | |
56 | 2.60E-07 | |
57 | 2.90E-07 | |
58 | 1.90E-06 | |
59 | 2.00E-08 | |
60 | 5.50E-08 | |
61 | 2.20E-07 | |
62 | 3.50E-07 | |
63 | 1.40E-06 | |
64 | 4.30E-08 | |
65 | 2.80E-07 | |
66 | 1.60E-08 | |
67 | 5.00E-08 | |
68 | 2.00E-07 | |
69 | 7.90E-08 | |
70 | 2.00E-07 | |
71 | 3.00E-07 | |
72 | 5.10E-07 | |
73 | >2.5E-05 | |
74 | 2.90E-07 | |
75 | 4.40E-07 | |
76 | 1.10E-06 |
100
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
77 | 1.30E-06 | |
78 | 1.50E-06 | |
79 | 2.40E-06 | |
80 | 2.80E-06 | |
81 | 3.00E-06 | |
82 | 3.60E-06 | |
83 | >2.5E-05 | |
84 | >2.5E-05 | |
85 | 2.10E-08 | |
86 | 1.40E-07 | |
87 | 3.80E-07 | |
88 | 2.40E-08 | |
89 | 2.80E-07 | |
90 | 3.40E-07 | |
91 | 6.40E-07 | |
92 | 2.30E-06 | |
93 | 9.00E-06 | |
94 | >2.5E-05 | |
95 | 2.50E-08 | 2.50E-08 |
96 | 1.00E-06 | 1.60E-06 |
97 | 6.90E-06 | 1.80E-06 |
98 | 3.80E-07 | 2.20E-06 |
99 | 7.80E-06 | 4.70E-06 |
100 | 5.70E-08 | 3.10E-07 |
101 | 3.90E-08 | 4.50E-07 |
102 | 4.50E-08 | 6.20E-07 |
103 | >2.5E-05 | 9.30E-07 |
104 | >2.5E-05 | 2.30E-06 |
105 | 2.20E-07 | |
106 | 3.30E-07 | |
107 | 3.20E-06 |
101
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
108 | 1.40E-05 | |
109 | 1.60E-07 | |
110 | 1.60E-07 | |
111 | 5.70E-07 | |
112 | 6.50E-07 | |
113 | 5.30E-07 | |
114 | 1.20E-06 | |
115 | 4.40E-06 | |
116 | 6.50E-06 | |
117 | >2.5E-05 | |
118 | 2.80E-08 | |
119 | 2.90E-06 | |
120 | 1.50E-06 | |
121 | 3.30E-06 | |
122 | 3.30E-08 | |
123 | 1.60E-06 | |
124 | 6.30E-06 | |
125 | 2.70E-06 | 2.30E-08 |
126 | >2.5E-05 | 2.10E-08 |
127 | 3.80E-07 | 4.30E-07 |
128 | 6.70E-06 | |
129 | 4.00E-08 | 8.00E-09 |
130 | 1.00E-05 | 1.50E-08 |
131 | 5.70E-07 | 5.10E-07 |
132 | 8.10E-06 | |
133 | 4.40E-06 | |
134 | >2.5E-05 | |
135 | 2.40E-07 | 1.60E-07 |
136 | 7.00E-08 | 2.00E-07 |
137 | 2.00E-07 | 2.30E-07 |
138 | >2.5E-05 | 9.60E-07 |
102
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
139 | >2.5E-05 | >2.5E-05 |
140 | 3.00E-08 | |
141 | 5.70E-08 | 5.40E-08 |
142 | 4.00E-08 | 2.60E-07 |
144 | 4.00E-08 | 3.30E-07 |
145 | 3.00E-08 | 2.50E-07 |
146 | 1.30E-05 | |
147 | 4.90E-07 | 5.50E-07 |
148 | 2.50E-07 | 1.20E-06 |
149 | 4.50E-06 | |
150 | >9.9E-05 | |
151 | 2.00E-05 | 1.50E-06 |
152 | 3.00E-08 | 4.00E-08 |
153 | 6.00E-08 | 8.10E-08 |
154 | 4.90E-08 | 1.10E-07 |
155 | 4.00E-08 | 4.40E-08 |
156 | 1.50E-07 | 2.00E-07 |
157 | 2.40E-07 | 1.70E-07 |
158 | 5.30E-07 | 2.40E-07 |
159 | 1.80E-06 | 2.90E-07 |
160 | 5.20E-07 | 4.60E-07 |
161 | >2.5E-05 | |
162 | >2.5E-05 | |
163 | 2.60E-07 | 1.70E-07 |
164 | 5.50E-07 | 6.80E-07 |
165 | 1.10E-07 | 9.20E-08 |
166 | 1.70E-07 | 1.10E-07 |
167 | 7.50E-08 | 1.30E-07 |
168 | 1.30E-07 | 2.20E-07 |
169 | 3.30E-07 | 5.60E-07 |
170 | 8.80E-07 | 1.10E-06 |
103
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
171 | 1.90E-06 | 8.10E-07 |
172 | 2.40E-07 | 2.80E-07 |
173 | >2.5E-05 | 1.50E-06 |
174 | 5.00E-06 | |
175 | 3.00E-08 | 7.90E-08 |
176 | 2.00E-08 | 3.40E-06 |
177 | 2.50E-07 | 4.40E-07 |
178 | 1.70E-06 | 1.70E-06 |
179 | ||
180 | >2.5E-05 | |
181 | 7.90E-07 | 3.00E-07 |
182 | 1.90E-06 | |
183 | >2.5E-05 | |
184 | 2.50E-07 | |
185 | 8.90E-07 | |
186 | 3.50E-07 | 2.40E-07 |
187 | 4.80E-07 | 3.00E-07 |
188 | 1.40E-07 | 8.40E-08 |
189 | 3.10E-07 | 9.80E-07 |
190 | 3.30E-06 | 4.20E-06 |
191 | 1.60E-06 | 1.10E-06 |
192 | 4.90E-07 | 1.00E-06 |
193 | 2.30E-05 | |
194 | 3.70E-07 | 8.20E-07 |
196 | 4.90E-06 | 1.60E-06 |
197 | 4.00E-07 | 3.10E-06 |
198 | 5.20E-06 | |
199 | 6.50E-06 | |
200 | 1.20E-05 | |
201 | 1.80E-07 | 4.10E-07 |
202 | >2.5E-05 |
104
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
203 | 3.60E-06 | 6.10E-06 |
204 | >2.5E-05 | |
205 | 4.40E-07 | 3.40E-07 |
206 | 1.20E-06 | 1.40E-06 |
207 | 8.20E-06 | 6.50E-06 |
208 | 1.60E-05 | 3.10E-06 |
209 | 3.30E-06 | |
210 | 7.50E-06 | |
211 | 7.40E-07 | |
212 | 2.60E-06 | |
213 | 6.00E-08 | 1.60E-07 |
214 | 9.60E-08 | 1.80E-07 |
215 | >2.5E-05 | |
216 | 5.40E-06 | |
217 | 1.20E-07 | |
218 | 4.10E-07 | |
219 | 5.80E-08 | |
220 | 2.70E-08 | |
221 | 1.70E-07 | |
222 | >2.5E-05 | |
223 | 8.40E-07 | |
224 | 3.00E-08 | |
225 | 2.10E-07 | |
226 | 8.20E-08 | |
227 | 2.10E-08 | |
228 | >2.5E-05 | |
229 | >2.5E-05 | |
230 | >2.5E-05 | |
231 | 8.70E-08 | |
232 | 2.20E-06 | |
233 | 3.90E-06 |
105
Compound No. | huBPGM:phosphatase Enzyme EC50 (M) | huBPGM:synthase Enzyme IC50 (M) |
234 | 1.30E-06 | |
235 | 1.30E-07 | |
236 | 1.10E-07 | |
237 | 2.20E-08 | |
238 | 4.90E-08 | |
239 | 4.80E-07 | 3.00E-07 |
[0257] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of ail patent and scientifïc literature cited herein are expressly incorporated herein in their entirety by référencé.
Claims (5)
1. A compound of Formula (I):
(D or a pharmaceutically acceptable sait thereof, wherein:
Ring A is a 5-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-C6 alkyl, C]-C6 haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-N(H)SO2(C6H5), -SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently Ci-C6 alkyl, Ci-C6 haloalkyl, or halo;
each R3 is independently Cj-Cô alkyl, Ci-C6 haloalkyl, or C3-C6 cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5,5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is 0-4;
n is 0-2;
o is 0-2;
R5 is phenyl or Ci-C6 alkyl;
X is -CR6R7- or a bond;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or Ci-Ce alkyl;
Z isZ’orZ2;
Z1 is H, C,-C6 alkyl, -C(O)(CrC6 alkyl), -CO2(CrC6 alkyl), -C(O)NR6R7, -C(O)NR6(Ci-C6 a!kylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(CrC6 alkylene)NR6R7, -NR6C(O)(CrC6 alkyl), -NR6R7, -(Ci-C6 alkyl)-CO2H, -(CrC6 alkyl)-OH, or-C(NR6R7)=N-CN,
107 wherein Ci-C6 alkylene is optionally substituted by 1-6 halo, Ci-C6 alkyl, or
Ci-Cô haloalkyl;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
-CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
-C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8;
each R8 is independently halo, CrC6 alkyl, Ci-C6 haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(C!-C6 alkyl), -CH2-O(CrC6 alkyl), or -(CrC6 alkyl>OH.
2. The compound of claim 1, wherein the compound is of Formula (I-a):
or a pharmaceutically acceptable sait thereof, wherein:
Ring A is thiazolylene;
Ring B is phenylene or a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, Ci-C6 alkyl, Ci-C6 haloalkyl, -CN, -N(H)C(0)R6, -N(H)SO2R6.-SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently CrC6 alkyl, Ci-C6 haloalkyl, or halo;
each R3 is independently Ci-C6 alkyl, C]-C6 haloalkyl, or C3-C6 cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is0-4;
n is0-2;
o is0-2;
R5 is phenyl or CrC6 alkyl;
108 is -CR6R7-;
Y is -O-, -N(H)-, or a bond;
each R6 and R7 is independently H or C|-C6 alkyl;
Z is Z2;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
-CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
-C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8; and each R8 is independently halo, Ci-C6 alkyl, C|-Cf) haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(C,-C6 alkyl), -CH2-O(CrC6 alkyl), or -(CrC6 alkyl)-OH.
3. The compound of claim 1, wherein the compound is of Formula (I-a 1 ):
or a pharmaceutically acceptable sait thereof, wherein:
Ring A is thiazolylene;
Ring B is a 5- to 6-membered heteroarylene containing 1-3 heteroatoms selected from N and S;
Ring C is a fused bicyclic 9- to 10-membered heteroaryl or phenyl substituted by one R4;
each R1 is independently -OH, halo, oxo, CrC6 alkyl, Ci-C6 haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6 -SO2NR6R7, or -C(O)N(H)SO2R6;
each R2 is independently Ci-C6 alkyl, Ci-C6 haloalkyl, or halo;
each R3 is independently C|-C6 alkyl, Ci-C6 haloalkyl, or C3-C6 cycloalkyl;
R4 is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and S, and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups;
m is 0-4;
n is 0-2;
o is 0-2;
R5 is phenyl or C]-C6 alkyl;
X is -CR6R7-;
109
Y is -O-, -N(H)-, or a bond;
each R6 and R7 ïs independently H or CrC6 alkyl;
Z is Z2;
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
-CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
-C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-3 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8; and each R8 is independently halo, Ci-C6 alkyl, Ci-C6 haloalkyl, -NR6R7, -OH, oxo, -CO2H,
-O(CrC6 alkyl), -CH2-O(C!-C6 alkyl), or -(CrC6 alkyl>OH.
4. The compound of claim 1, or a pharmaceutically acceptable sait thereof, wherein Ring A is thiazolylene.
5. The compound of any one of daims 1-3, or a pharmaceutically acceptable sait thereof, wherein each R3 is independently C1-C3 alkyl or C3-C6 cycloalkyl.
6. The compound of claim 4, or a pharmaceutically acceptable sait thereof, wherein each R3 is independently -CH3 or cyclopropyl.
7. The compound of any one of daims 1-5, or a pharmaceutically acceptable sait thereof, wherein o is 0 or 1.
8. The compound of any one of daims 1-2 or 4-7, or a pharmaceutically acceptable sait thereof, wherein Ring B is phenylene, pyridinylene, thiazolylene, pyrazolylene, pyrimidinylene, or thienylene.
9. The compound of any one of daims 1-8, or a pharmaceutically acceptable sait thereof, wherein each R2 is independently CrC3 alkyl or halo.
10. The compound of any one of daims 1-9, or a pharmaceutically acceptable sait thereof, wherein n is 0 or 1.
11. The compound of any one of daims 1-2 and 4-11, or a pharmaceutically acceptable sait thereof, wherein:
110 ît Ring C
is a fused bicyclic 9-membered heteroaryl or heterocyclyl containing 1-4 heteroatoms selected from N and O, a 5- to 6-membered heteroaryl containing 1-4 nitrogen atoms, or phenyl substituted by one R4.
5
12.
The compound of any one of daims 1-11, or a pharmaceutically acceptable sait thereof, wherein: è
R4
is -OH, -OP(O)(OH)2, -NO2, -C(O)N(H)SO2R5, 5- to 6-membered heteroaryl or heterocyclyl, or -C(O)N(H)-(5- to 6-membered heteroaryl or heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-4 heteroatoms selected from N, O, and
10
s,
and wherein the heterocyclyl is optionally substituted by 1-2 oxo groups; and
R5
is phenyl or C1-C3 alkyl.
13.
The compound of any one of daims 1-2 and 4-12, or a pharmaceutically acceptable sait
15
thereof, wherein:
Ring C-(R’)m is selected from:
111
14. The compound of any one of claims 1-13, or a pharmaceutically acceptable sait thereof, wherein:
5 each R1 is independently -OH, halo, oxo, C1-C3 alkyl, C1-C3 haloalkyl, -CN, -N(H)C(O)R6, -N(H)SO2R6,-SO2NR6R7, or -C(O)N(H)SO2R6; and each R6 and R7 is independently H or C1-C3 alkyl.
15. The compound of any one of claims 1-13, or a pharmaceutically acceptable sait thereof,
10 wherein:
each R1 is independently -OH, F, oxo, -CH3, -CN, -N(H)C(O)CH3, -N(H)SO2(C6H5), -N(H)SO2CH3, -SO2NH2, or-C(O)N(H)SO2CH3.
16. The compound of any one of claims 1-15, or a pharmaceutically acceptable sait thereof, wherein m is 0-3.
112
17. The compound of any one of claims 1 and 4-16, or a pharmaceutically acceptable sait thereof, wherein X is -CR6R7-.
18. The compound of any one of claims 1-3 and 17, or a pharmaceutically acceptable sait thereof, wherein R6 and R7 are each H.
19. The compound of any one of claims 1 and 4-16, or a pharmaceutically acceptable sait thereof, wherein X is a bond.
20. The compound of any one of claims 1-19, or a pharmaceutically acceptable sait thereof, wherein Y is -O-.
21. The compound of any one of claims 1-19, or a pharmaceutically acceptable sait thereof, wherein Y is -N(H)- or a bond.
22. The compound of any one of claims 1 and 4-21, or a pharmaceutically acceptable sait thereof, wherein Z is Z1.
23. The compound of claim 22, or a pharmaceutically acceptable sait thereof, wherein: Z1 is H, CrC3 alkyl, -C(O)(C,-C3 alkyl), -CO2(CrC3 alkyl), -C(O)NR6R7,
-C(O)NR6(C,-C3 alkylene)NR6R7, -CR6R7C(O)NR6R7, -CR6R7NR6R7, -C(O)(C,-C3 alkylene)NR6R7, -NR6C(O)(CrC3 alkyl), -NR6R7, -(C,-C3 alkyl)-CO2H, -(C,-C3 alkyl)-OH, or -C(NR6R7)=N-CN, wherein C|-C3 alkylene is optionally substituted by 1-2 halo, CrC3 alkyl, or C]-C3 haloalkyl; and each R6 and R7 is independently H or Ci-C3 alkyl.
24. The compound of claim 22, or a pharmaceutically acceptable sait thereof, wherein: Z1 is H, -CO2CH3, -CO2C(CH3)3, -C(O)CH3, -C(O)C(CH3)3, -C(N(CH3)2)=N-CN,
-C(O)N(CH3)2, -CH3, -CH2CH3, -CH2C(CH3)3, -CH2CO2H, -CH2C(CH3)2OH, -C(O)N(CH3)CH2CH2N(CH3)2, -CH2C(O)N(CH3)2, -CH(CH3)C(O)N(CH3)2, -N(CH3)2, -N(CH3)C(O)CH3, or -C(O)CH(CH3)CH2N(CH3)2.
25. The compound of any one of claims 1-21, or a pharmaceutically acceptable sait thereof, wherein Z is Z2.
113
26.
The compound of claim 24, or a pharmaceutically acceptable sait thereof, wherein:
Z2 is 5- to 6-membered heteroaryl, -C(O)(5- to 6-membered heteroaryl),
-CH2C(O)(5- to 6-membered heteroaryl), 4- to 6-membered heterocyclyl,
-C(O)(4- to 6-membered heterocyclyl), or -CH2C(O)(4- to 6-membered heterocyclyl), wherein the heteroaryl and heterocyclyl contain 1-2 heteroatoms selected from N and O, and wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8.
27. The compound of claim 25, or a pharmaceutically acceptable sait thereof, wherein:
Z2 is pyrimidinyl, pyridazinyl, pyrrolidinyl, piperidinyl, pyridazinyl,
-C(O)(tetrahydropyranyl), -C(O)(pyrrolidinyl), -C(O)(pyridazinyl),
-C(O)(piperidinyl), -C(O)(azetidinyl), -C(O)(pyrazolyI), -C(O)(piperazinyl), -CH2C(O)(pyrrolidinyl), -CH2C(O)(piperidinyl), or -CH2C(O)(piperazinyl), wherein the heteroaryl and heterocyclyl are optionally substituted by 1-3 R8.
28. The compound of any one of daims 1-21 and 25-27, or a pharmaceutically acceptable sait thereof, wherein:
each R8 is independently halo, C,-C3 alkyl, C,-C3 haloalkyl, -NR6R7, -OH, oxo, -CO2H, -O(Ci-C3 alkyl), -0Η2-Ο(Ο-03 alkyl), or -(0,-03 alkyl)-OH; and each R6 and R7 is independently H or Ci-C3 alkyl.
29. The compound of claim 28, or a pharmaceutically acceptable sait thereof, wherein: each R8 is independently -CH3, -CH2CH3, -NH2, -OH, oxo, -N(CH3)2, -OCH3, -CH2OCH3,
-CF3, -CH2CH2OH, -CO2H, or CL
30. The compound of claim 1, or a pharmaceutically acceptable sait thereof, wherein Z-Y-X- is:
114
-ch2oh
-OCH2CH3 , or -CH2OCH3
31. The compound of claim 1, or a pharmaceutically acceptable sait thereof, wherein Z-Y-Xis:
HO
115
32. A compound selected from the compounds in Table l, or a pharmaceutically acceptable sait thereof.
5 33. A compound selected from the compounds in Table 2, or a pharmaceutically acceptable sait thereof.
34.
A pharmaceutical composition comprising the compound of any one of claims 1-33, or a pharmaceutically acceptable sait thereof, and at least one pharmaceutically acceptable excipient.
116 «4 35·
5 36.
A compound of any one of claims 1-33, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of claim 34, for use in a method of modulating bisphosphoglycerate mutase (BPGM).
A compound of any one of claims 1-33, or a pharmaceutically acceptable sait thereof, or the pharmaceutical composition of claim 34, for use in a method of treating sickle cell disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/077,973 | 2020-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA21204A true OA21204A (en) | 2024-02-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11649233B2 (en) | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | |
TWI444378B (en) | Sulfur containing heterocyclic derivatives having β secretase inhibitory activities and use thereof | |
JP2020525522A (en) | RHO-related protein kinase inhibitor, pharmaceutical composition containing the same, preparation method and use thereof | |
CN103124730A (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
WO2011075560A1 (en) | Aminopyrimidines as syk inhibitors | |
AU2017237930A1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
JP2015503529A5 (en) | ||
IL285246B1 (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
US20140249134A1 (en) | Triazolyl pde10 inhibitors | |
AU2021339298A1 (en) | Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof | |
EP4305022A1 (en) | Anti-viral compounds | |
JP2022527294A (en) | Compounds and compositions as regulators of TLR signaling | |
US20220106296A1 (en) | Cyanotriazole compounds and uses thereof | |
JP6389531B2 (en) | Anti-enterovirus 71 thiadiazolidine derivative | |
OA21204A (en) | Compounds as modulators of bisphosphoglycerate mutase for the treatment of sickle cell disease. | |
AU2021339844A9 (en) | Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease | |
US20230339927A1 (en) | Atr inhibitors and uses thereof | |
EP4211121A1 (en) | Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease | |
US10570117B2 (en) | Phenylimidazole compound | |
CA3229397A1 (en) | Aromatic ring-containing biological antagonist, and preparation method therefor and use thereof |